前往化源商城

1968-05-4 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OPM1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011890.089787Complete curve; high efficacy-7.92922.47290.96942.5966132.6862-1.10 0 0 0 0 0 0 0 0 0 057.466123.2938140.8388112.24160.901644.089639.767736.478540.20639.176941.461857.466QC'd by ChemAxon
Cytotoxic0.417675.850987Complete curve; high efficacy-6.37921.53860.949872.4265148.2774-1.10 0 0 0 0 0 0 0 0 0 061.5626139.2774158.5971143.0204144.9664147.8567136.015191.815692.950575.674674.676861.5626QC'd by JohnsHopkins
Cytotoxic0.148294.419287Complete curve; high efficacy-6.82921.10.951759.4372153.8564-1.10 0 0 0 0 0 0 0 0 0 055.0456164.8354134.704151.2303143.6834134.761595.648470.062167.305676.105555.692455.0456QC'd by Selleck
Cytotoxic0.166394.102386Complete curve; high efficacy-6.77922.72020.972950.0751144.1775-1.10 0 0 0 0 0 0 0 0 0 056.0568132.0924142.9387160.1371137.1338142.289985.893148.200245.041752.603354.183256.0568QC'd by ACC
Cytotoxic0.0332121.075286Complete curve; high efficacy-7.479210.984142.1192163.1944-1.10 0 0 0 0 0 0 0 0 0 035.7472158.2854158.4708139.505123.340671.574165.258955.071850.086742.178237.195535.7472QC'd by Selleck
Cytotoxic0.742778.671685Complete curve; high efficacy-6.12921.88510.983463.6148142.2865-1.10 0 0 0 0 0 0 0 0 0 058.2475142.1116146.4992135.5304145.8795136.7066141.0466113.833174.38665.128871.886858.2475QC'd by Tocris
Cytotoxic0.833386.219185Complete curve; high efficacy-6.079210.930267.549153.7681-1.10 0 0 0 0 0 0 0 0 0 069.8532158.4753142.7847153.7541141.7507166.925141.693105.2958104.667477.221776.165269.8532QC'd by Tocris
Cytotoxic3.722164.493585Complete curve; high efficacy-5.42924.95490.792112.0642176.5577-1.10 0 0 0 0 0 0 0 0 0 089.6942158.9633166.2699180.3984167.1951174.9654191.2964181.3214193.1909122.0222135.538889.6942QC'd by Tocris
Cytotoxic0.0526123.236885Complete curve; high efficacy-7.27920.60.972433.4065156.6433-1.10 0 0 0 0 0 0 0 0 0 035.7651153.6951126.1364142.4363103.249192.595173.147860.614343.388740.031337.882135.7651QC'd by Tocris
Cytotoxic0.006677.526284Complete curve; high efficacy-8.17920.80.975321.696999.2231-1.10 0 0 0 0 0 0 0 0 0 013.262791.55276.413756.561242.193434.028331.180927.350626.077820.634320.214413.2627QC'd by Tocris
Cytotoxic0.5258123.459984Complete curve; high efficacy-6.27921.39870.968242.1223165.5821-1.10 0 0 0 0 0 0 0 0 0 025.7016164.86160.7689152.0063170.1205168.2257149.303488.213874.069651.798249.790125.7016QC'd by JohnsHopkins
Cytotoxic1.865582.375984Complete curve; high efficacy-5.72922.33320.929161.702144.078-1.10 0 0 0 0 0 0 0 0 0 051.7606136.01140.2451152.6106148.0124143.6336147.0904134.4052111.284254.479484.371251.7606QC'd by Selleck
Cytotoxic2.3485101.924784Complete curve; high efficacy-5.62920.60.955871.9549173.8795-1.10 0 0 0 0 0 0 0 0 0 091.649176.6761171.0851177.7813159.9071159.3009150.4576153.7054126.8633116.427184.815491.649QC'd by SynKinase
Cytotoxic0.018790.923784Complete curve; high efficacy-7.72920.70.995926.7347117.6584-1.10 0 0 0 0 0 0 0 0 0 029.5723109.5774101.759683.749673.379952.652141.5735.435430.241226.675925.387729.5723QC'd by Microsource
Cytotoxic0.0132127.373583Complete curve; high efficacy-7.87920.70.972217.3385144.712-1.10 0 0 0 0 0 0 0 0 0 033.7384132.8301113.247589.341775.717555.400227.741422.107814.440214.011616.778533.7384QC'd by Tocris
Cytotoxic3.722186.014283Complete curve; high efficacy-5.42921.210.972165.5416151.5558-1.10 0 0 0 0 0 0 0 0 0 066.7748154.8648146.5307153.6238147.9405153.7843144.2907154.4262119.8728100.256583.011166.7748QC'd by Tocris
Cytotoxic0.3722105.789883Complete curve; high efficacy-6.42922.84730.98436.148141.9378-1.10 0 0 0 0 0 0 0 0 0 022.8052141.9378142.9518145.1156141.0583137.6217130.508557.913351.266941.388233.000722.8052QC'd by JohnsHopkins
Cytotoxic1.6626102.314483Complete curve; high efficacy-5.779210.924240.9668143.2813-1.10 0 0 0 0 0 0 0 0 0 047.0105152.3961124.7264140.9824142.6059141.9566147.0368112.397281.287385.089138.460247.0105QC'd by Microsource
Cytotoxic0.0118140.01383Complete curve; high efficacy-7.92922.58840.998217.9926158.0057-1.10 0 0 0 0 0 0 0 0 0 014.8749156.5885154.4434130.9445.126815.310417.374218.814419.415621.188621.270814.8749QC'd by Selleck
Cytotoxic0.4686118.608983Complete curve; high efficacy-6.32921.85790.987228.1061146.7151-1.10 0 0 0 0 0 0 0 0 0 027.0205138.0525155.3457144.6536140.3247148.8544132.291370.355346.41333.133522.075327.0205QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OC1MY5-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.016675.705499Complete curve; high efficacy-7.77921.62590.8287113.3664189.0718-1.10 0 0 0 0 0 0 0 0 0 076.415189.0718184.1323176.4162143.7765121.3848112.8196136.1769124.1622121.4205110.84976.415QC'd by SigmaAldrich
Cytotoxic0.014878.323895Complete curve; high efficacy-7.82921.88510.884990.161168.4848-1.10 0 0 0 0 0 0 0 0 0 067.4943179.706152.1469156.7226115.95190.887181.242794.0684108.643892.5891100.356267.4943QC'd by BIOMOL
Cytotoxic0.0093193.289593Complete curve; high efficacy-8.02920.50.866672.6851265.9745-1.10 0 0 0 0 0 0 0 0 0 0105.1458244.5929174.7663172.838154.9069132.1222117.372990.589987.865585.670530.7772105.1458QC'd by Microsource
Cytotoxic0.0021162.783989Complete curve; high efficacy-8.67922.25260.909541.4972204.2812-1.10 0 0 0 0 0 0 0 0 0 016.0569187.9512112.283154.611932.400643.04248.563547.468974.45340.548125.593516.0569QC'd by Tocris
Cytotoxic0.0037168.183989Complete curve; high efficacy-8.42921.98870.95444.8326213.0165-1.10 0 0 0 0 0 0 0 0 0 016.7704206.3802163.409786.454636.022349.839739.359743.293852.688461.372857.854816.7704QC'd by Waterstone
Cytotoxic0.0469148.810689Complete curve; high efficacy-7.32922.40640.8561.7336210.5442-1.10 0 0 0 0 0 0 0 0 0 08.2046222.3206202.2319203.978192.1974118.262335.92446.047760.9187116.720798.87498.2046QC'd by ChemAxon
Cytotoxic0.0026113.270989Complete curve; high efficacy-8.57923.1320.897742.9988156.2697-1.10 0 0 0 0 0 0 0 0 0 021.2361152.3367113.413840.593638.127740.362443.602334.137943.871364.736864.064821.2361QC'd by Tocris
Cytotoxic0.0017114.495389Complete curve; high efficacy-8.77924.0950.841643.8532158.3484-1.10 0 0 0 0 0 0 0 0 0 014.1898152.803967.85254.519352.359357.345849.82462.059347.505430.836728.465514.1898QC'd by Selleck
Cytotoxic0.002672.734289Complete curve; high efficacy-8.57922.72020.907441.83114.5643-1.10 0 0 0 0 0 0 0 0 0 049.3766112.187583.595146.53530.954733.435532.312943.245244.089344.797856.003549.3766QC'd by Microsource
Cytotoxic0.0743128.224189Complete curve; high efficacy-7.12920.30.807365.0905193.3146-1.10 0 0 0 0 0 0 0 0 0 071.5247186.4209158.6743129.1227120.8146138.5824133.4969104.1228120.2992101.960377.775671.5247QC'd by Tocris
Cytotoxic0.0662125.720489Complete curve; high efficacy-7.17921.82650.971967.5385193.259-1.10 0 0 0 0 0 0 0 0 0 052.5197186.6163181.5655200.1337192.1342128.241283.363287.409864.631570.685465.116152.5197QC'd by SantaCruz Bio
Cytotoxic0.661978.285988Complete curve; high efficacy-6.17921.88510.946996.3016174.5875-1.10 0 0 0 0 0 0 0 0 0 0101.3711171.7651176.8613184.4702181.7039154.2237171.0284143.1726100.579190.9185104.0348101.3711QC'd by BIOMOL
Cytotoxic0.0935125.731288Complete curve; high efficacy-7.02923.990.970262.9518188.683-1.10 0 0 0 0 0 0 0 0 0 071.3789173.2237176.4213202.4283200.5745169.056972.067947.835455.511865.182873.840471.3789QC'd by Selleck
Cytotoxic0.0743119.127488Complete curve; high efficacy-7.12920.70.98858.8412177.9686-1.10 0 0 0 0 0 0 0 0 0 065.4007172.7284171.0856155.1599146.3776116.585999.779291.984365.419864.002856.279365.4007QC'd by Axon Medchem
Cytotoxic0.3317103.910288Complete curve; high efficacy-6.47920.30.843677.4858181.396-1.10 0 0 0 0 0 0 0 0 0 0101.3477161.302177.473153.8803133.2684139.1275144.3925135.8497117.608691.5334104.8313101.3477QC'd by Tocris
Cytotoxic0.1321123.71788Complete curve; high efficacy-6.879210.962367.9127191.6297-1.10 0 0 0 0 0 0 0 0 0 045.8939178.5371199.9241184.0193181.5655149.5884112.02994.762981.731373.616983.205245.8939QC'd by Microsource
Cytotoxic0.0066144.59188Complete curve; high efficacy-8.17922.72020.931843.5813188.1723-1.10 0 0 0 0 0 0 0 0 0 07.9675169.8483200.8523105.256949.605442.518545.303152.145650.632956.794649.51437.9675QC'd by SIGMA
Cytotoxic0.935111.476387Complete curve; high efficacy-6.02921.46410.907288.9886200.4649-1.10 0 0 0 0 0 0 0 0 0 065.9282174.089200.6763211.7975212.4609203.6327185.8171171.8065108.7421105.1811115.181865.9282QC'd by Selleck
Cytotoxic0.0118148.747387Complete curve; high efficacy-7.92921.88510.914741.9403190.6876-1.10 0 0 0 0 0 0 0 0 0 08.0822198.2962171.9006154.032174.692245.681859.094162.628163.424350.903813.29568.0822QC'd by Selleck
Cytotoxic1.662684.625787Complete curve; high efficacy-5.77922.72020.9593106.2986190.9242-1.10 1 0 0 0 0 0 0 0 0 0104.8088197.9176147.6744188.5439182.4788196.4457175.6724199.742148.305107.0547110.4851104.8088QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:G-protein coupled receptor 35
External ID: CHEMBL4015240
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593

Target ChEMBL ID: CHEMBL1293267
ChEMBL Target Name: G-protein coupled receptor 35
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeActivity Comment
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Aryl hydrocarbon receptor
External ID: CHEMBL4015241
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593

Target ChEMBL ID: CHEMBL3201
ChEMBL Target Name: Aryl hydrocarbon receptor
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeActivity Comment
ActivityDose-dependent effect
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS_34-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.041888.877985Complete curve; high efficacy-7.37921.210.83931.4966120.3746-1.10 0 0 0 0 0 0 0 0 0 07.7124132.8926100.448796.9022107.952767.422923.232138.254730.074155.763343.34537.7124QC'd by ChemAxon
Cytotoxic0.0148116.450385Complete curve; high efficacy-7.82920.40.883227.623144.0733-1.10 0 0 0 0 0 0 0 0 0 023.9089133.149384.985690.676488.203880.547548.934346.794939.846148.370238.326523.9089QC'd by Tocris
Cytotoxic0.00363.507484Complete curve; high efficacy-8.52921.24750.846222.061585.5689-1.10 0 0 0 0 0 0 0 0 0 04.685578.444856.901238.37827.125924.86230.850833.175427.356122.258211.85044.6855QC'd by AG Scientific
Cytotoxic0.066281.534784Complete curve; high efficacy-7.17920.50.935226.2812107.8158-1.10 0 0 0 0 0 0 0 0 0 041.7013104.6491.691185.710374.992566.250263.828947.143640.11632.645316.398141.7013QC'd by Microsource
Cytotoxic0.005388.857983Complete curve; high efficacy-8.27920.70.918715.3166104.1745-1.10 0 0 0 0 0 0 0 0 0 017.273995.7755.043766.176737.487330.62723.923816.028919.552917.45899.815517.2739QC'd by Toronto Research
Cytotoxic0.209387.781383Complete curve; high efficacy-6.67923.06540.98628.7833116.5646-1.10 0 0 0 0 0 0 0 0 0 028.0348105.4018124.2663111.216120.9286117.829382.793730.938430.822427.522130.01228.0348QC'd by ACC
Cytotoxic0.016684.33283Complete curve; high efficacy-7.77922.72020.984217.1644101.4964-1.10 0 0 0 0 0 0 0 0 0 016.809492.1572111.714893.822544.879723.29116.702114.931216.05218.314117.449816.8094QC'd by ChemAxon
Cytotoxic0.037278.620483Complete curve; high efficacy-7.42922.58840.984618.797997.4182-1.10 0 0 0 0 0 0 0 0 0 012.888592.420695.8169102.935482.036534.503824.164219.157513.771216.322226.468312.8885QC'd by Selleck
Cytotoxic1.04996.497783Complete curve; high efficacy-5.97920.50.957536.2422132.7399-1.10 0 0 0 0 0 0 0 0 0 054.2766130.3979127.8742134.2077109.0067109.1952107.713199.92678.571159.936952.628454.2766QC'd by LINCS
Cytotoxic0.0469113.5983Complete curve; high efficacy-7.32921.92820.977620.8655134.4556-1.10 0 0 0 0 0 0 0 0 0 021.4008136.3735118.7418147.5619108.852467.204221.009224.201124.538819.698820.300321.4008QC'd by Tocris
Cytotoxic0.0059134.11483Complete curve; high efficacy-8.22920.90.958214.3732148.4872-1.10 0 0 0 0 0 0 0 0 0 07.7187135.6994.255592.291235.67427.57326.610323.447918.96313.139211.28037.7187QC'd by Selleck
Cytotoxic0.016682.99983Complete curve; high efficacy-7.77924.44950.914818.7882101.7872-1.10 0 0 0 0 0 0 0 0 0 01.306589.3692109.2888105.280939.259712.56078.63117.245227.937241.290725.02181.3065QC'd by BIOMOL
Cytotoxic0.0026124.131382Complete curve; high efficacy-8.57921.47810.986411.3246135.4559-1.10 0 0 0 0 0 0 0 0 0 014.9487124.278272.55539.097213.763318.160410.303510.566110.76498.90756.618214.9487QC'd by Tocris
Cytotoxic0.0209112.54382Complete curve; high efficacy-7.67921.96730.932614.5764127.1195-1.10 0 0 0 0 0 0 0 0 0 00.7959123.8363116.6866132.122462.186831.22417.327713.62456.960345.1415.10240.7959QC'd by NCGCChem
Cytotoxic0.104980.762282Complete curve; high efficacy-6.97923.990.931416.214996.9771-1.10 0 0 0 0 0 0 0 0 0 02.1195101.382375.2262112.248999.869687.632124.000528.457125.40816.87938.90662.1195QC'd by ChemAxon
Cytotoxic0.234892.655582Complete curve; high efficacy-6.62920.90.986616.7612109.4167-1.10 0 0 0 0 0 0 0 0 0 013.3983112.307799.4639110.160599.618592.250163.412843.116934.989225.203720.221113.3983QC'd by JohnsHopkins
Cytotoxic0.0264105.223682Complete curve; high efficacy-7.57922.78680.988110.1409115.3645-1.10 0 0 0 0 0 0 0 0 0 05.3828108.8197112.7123124.379475.066919.974411.747517.45588.74528.59417.9615.3828QC'd by Selleck
Cytotoxic0.93588.261382Complete curve; high efficacy-6.02921.78850.855620.4336108.6949-1.10 0 0 0 0 0 0 0 0 0 04.852785.5635121.1104117.096194.650799.9913137.032269.811848.833229.794829.96994.8527QC'd by Selleck
Cytotoxic0.0059119.868782Complete curve; high efficacy-8.22920.90.98910.4647130.3334-1.10 0 0 0 0 0 0 0 0 0 09.7544119.720688.055968.561935.492830.376516.190110.80912.106211.21728.0079.7544QC'd by Tocris
Cytotoxic0.4176152.652182Complete curve; high efficacy-6.37920.40.9686-18.9995133.6526-1.10 0 0 0 0 0 0 0 0 0 02.9146127.427102.6532123.629693.093583.859362.24155.771444.320918.43846.1372.9146QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Free fatty acid receptor 4
External ID: CHEMBL4015239
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593

Target ChEMBL ID: CHEMBL5339
ChEMBL Target Name: G-protein coupled receptor 120
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_L363-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011864.8887Complete curve; high efficacy-7.92923.990.906542.9911107.8711-1.10 0 0 0 0 0 0 0 0 0 175.9379117.166298.059101.666744.543237.931551.79645.54545.89855.696524.21575.9379QC'd by ChemAxon
Cytotoxic0.001086Complete curve; high efficacy-900.8727.00327.003-1.10 0 0 0 0 0 0 0 0 0 011.714116.109651.782338.477438.14932.576327.00321.712513.65628.24944.831811.714QC'd by Tocris
Cytotoxic0.014887.3385Complete curve; high efficacy-7.82922.72020.839428.2225115.5525-1.10 0 0 0 0 0 0 0 0 0 02.7164112.6565118.5558105.208650.461432.896456.123844.203245.685613.05273.96712.7164QC'd by ChemAxon
Cytotoxic0.074381.047985Complete curve; high efficacy-7.12922.40640.987736.057117.1048-1.10 0 0 0 0 0 0 0 0 0 036.612118.1815112.941121.7674108.916987.133342.59131.000532.05139.154343.592636.612QC'd by Selleck
Cytotoxic0.013295.183485Complete curve; high efficacy-7.87922.58840.978930.3117125.4951-1.10 0 0 0 0 0 0 0 0 0 022.3434119.5176131.0238109.768849.199641.232339.094429.184232.449924.950225.888622.3434QC'd by Tocris
Cytotoxic0.037296.952684Complete curve; high efficacy-7.42923.67720.943926.3959123.3485-1.10 0 0 0 0 0 0 0 0 0 020.4921101.7407120.2132147.5217112.769437.937439.317124.381225.076727.694220.417320.4921QC'd by Selleck
Cytotoxic0.1147102.026284Complete curve; high efficacy-6.94040.40.945728.8277130.8539-1.10 0 0 0 0 0 0 0 0 0 1108.0014122.9006125.5314115.924689.870995.612875.420675.658466.669245.064945.6837108.0014QC'd by Selleck
Cytotoxic0.009390.158484Complete curve; high efficacy-8.02921.71370.962524.1405114.2989-1.10 0 0 0 0 0 0 0 0 0 020.1633106.7519116.404475.80742.460431.644837.517319.116617.345730.109618.866820.1633QC'd by NCGCChem
Cytotoxic0.468669.609184Complete curve; high efficacy-6.32921.69240.827647.7156117.3247-1.10 0 0 0 0 0 0 0 0 0 195.324899.0689105.4815112.5472134.071139.294895.863678.07556.20561.315734.97695.3248QC'd by Microsource
Cytotoxic0.295785.225883Complete curve; high efficacy-6.52924.95490.905530.0023115.2281-1.10 0 0 0 0 0 0 0 0 1 045.1208102.1961108.7224107.4279107.404145.4631114.174621.348922.64833.189677.55645.1208QC'd by NCGCChem
Cytotoxic0.0118107.387883Complete curve; high efficacy-7.92924.44950.994618.1514125.5392-1.10 0 0 0 0 0 0 0 0 0 1103.6539130.2388120.1313117.134124.788321.804212.746820.289419.91221.366715.3748103.6539QC'd by Selleck
Cytotoxic0.033278.333383Complete curve; high efficacy-7.47924.44950.957520.808999.1422-1.10 0 0 0 0 0 0 0 0 0 1105.677694.56286.401118.767388.388324.521523.716318.859423.322922.567716.9857105.6776QC'd by Chemscene
Cytotoxic0.011886.29183Complete curve; high efficacy-7.92920.910.971220.4028106.6938-1.10 0 0 0 0 0 0 0 0 0 013.990798.3598100.650970.772445.884940.959433.218425.044519.165723.31217.822613.9907QC'd by Selleck
Cytotoxic0.234884.542283Complete curve; high efficacy-6.62921.10.954725.2427109.7849-1.10 0 0 0 0 0 0 0 0 0 1114.3833102.02113.1558103.8422121.074381.328372.684251.920531.812126.372328.0582114.3833QC'd by ChemieTek
Cytotoxic0.014886.1283Complete curve; high efficacy-7.82922.18760.972516.3085102.4286-1.10 0 0 0 0 0 0 0 0 0 07.9507102.926198.733390.777842.92222.299723.200730.230611.653910.657913.08247.9507QC'd by Selleck
Cytotoxic0.148277.093883Complete curve; high efficacy-6.82924.95490.955322.412899.5066-1.10 0 0 0 0 0 0 0 0 0 09.87102.096792.544998.652790.3526113.472742.025228.643431.5424.979314.77199.87QC'd by Chemscene
Cytotoxic0.417691.373683Complete curve; high efficacy-6.37921.69240.985829.7282121.1017-1.10 0 1 0 0 0 0 0 0 0 021.3801116.2452129.3034186.5441118.5918113.5565105.088162.785435.762934.74535.353721.3801QC'd by Selleck
Cytotoxic1.04987.361683Complete curve; high efficacy-5.979210.877236.1973123.5589-1.10 0 0 0 0 0 0 0 0 0 054.1491117.4289109.6638131.7472129.0154136.577793.933688.945583.642543.457225.12354.1491QC'd by SynKinase
Cytotoxic0.1482113.990583Complete curve; high efficacy-6.82921.28760.888823.8075137.7981-1.10 0 0 0 0 0 0 0 0 0 08.0453114.2505119.5624176.2421137.6679106.682559.028455.250738.182324.837127.40678.0453QC'd by Tocris
Cytotoxic1.17785.496383Complete curve; high efficacy-5.92923.62720.914939.2135124.7097-1.10 0 0 0 0 0 0 0 0 0 027.6517113.2381135.3021111.0564135.5045142.3677111.5001118.811556.830633.204257.637227.6517QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Free fatty acid receptor 1
External ID: CHEMBL4015236
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593

Target ChEMBL ID: CHEMBL4422
ChEMBL Target Name: Free fatty acid receptor 1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeActivity Comment
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OCIMY7-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0148138.417292Complete curve; high efficacy-7.82920.80.985473.4473211.8645-1.10 0 0 0 0 0 0 0 0 0 076.0615206.4576176.3477160.675143.036102.215687.458676.386675.942381.513271.284576.0615QC'd by Selleck
Cytotoxic0.1865129.709492Complete curve; high efficacy-6.72922.47290.9102104.5908234.3002-1.10 0 0 0 0 0 0 0 0 0 097.9499212.7695199.584247.0735277.3731227.6905162.5507123.8591102.5004104.1059104.398997.9499QC'd by SantaCruz Bio
Cytotoxic0.525872.960991Complete curve; high efficacy-6.27922.72020.9263121.6641194.625-1.10 0 0 0 0 0 0 0 0 0 1182.846196.2276201.2704206.5478177.6678187.1047193.8819153.4274124.7553110.5225133.7805182.846QC'd by SIGMA
Cytotoxic0.0469134.726691Complete curve; high efficacy-7.32922.33320.942779.2711213.9977-1.10 0 0 0 0 0 0 0 0 0 074.524225.8348183.7696233.1661192.207130.243974.8439101.457875.21388.15864.064774.524QC'd by Selleck
Cytotoxic0.001091Complete curve; high efficacy-900.973648.780348.7803-1.10 0 0 0 0 0 0 0 0 0 047.83166.158106.533567.344835.203147.280344.656348.780346.703651.704556.888247.83QC'd by Tocris
Cytotoxic0.001090Complete curve; high efficacy-900.820746.422646.4226-1.10 0 0 0 0 0 0 0 0 0 05.4032205.1041113.398945.042360.965955.970682.491946.422618.259210.66488.46975.4032QC'd by Tocris
Cytotoxic1.481867.805689Complete curve; high efficacy-5.82924.95490.7621141.433209.2386-1.10 0 0 0 0 0 0 0 0 0 0116.0869187.3686222.298199.2101217.5801185.2508221.0682234.3031161.6854158.4572150.9575116.0869QC'd by ChemAxon
Cytotoxic0.001089Complete curve; high efficacy-900.959138.870638.8706-1.10 0 0 0 0 0 0 0 0 0 039.1109165.4745147.989392.122638.870647.652815.964314.55779.16457.80787.070839.1109QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.938841.142141.1421-1.10 0 0 0 0 0 0 0 0 0 03.8961184.0933141.73391.783118.669184.427141.142140.416126.249718.52235.72733.8961QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.988840.837940.8379-1.11 0 0 0 0 0 0 0 0 0 026.1407121.6554195.8384155.511388.106368.094737.765640.837940.099127.971631.77326.1407QC'd by Selleck
Cytotoxic0.038292.573488Complete curve; high efficacy-7.4180.40.889752.7945145.3679-1.10 0 0 0 0 0 0 0 0 0 051.9291116.2057136.3435103.092491.965479.473982.026983.101367.37361.55557.499951.9291QC'd by ChemPacific
Cytotoxic0.0743134.535488Complete curve; high efficacy-7.12921.210.930757.9113192.4467-1.10 0 0 0 0 0 0 0 0 0 049.7147175.8519207.2976185.8686162.8742143.048663.049199.107467.380557.937949.251549.7147QC'd by ChemAxon
Cytotoxic0.001088Complete curve; high efficacy-900.875833.721233.7212-1.10 0 0 0 0 0 0 0 0 0 04.1324152.461297.589368.749932.264258.815947.257833.72128.80494.81863.54334.1324QC'd by Microsource
Cytotoxic3.722185.223987Complete curve; high efficacy-5.42924.95490.891150.0271235.251-1.11 0 0 0 0 0 0 0 0 0 0154.7033204.9209231.691212.9559243.8102227.9286234.025230.2626264.0915159.589149.6383154.7033QC'd by SIGMA
Cytotoxic1.3207106.100387Complete curve; high efficacy-5.87921.82650.9417105.4088211.509-1.10 0 0 0 0 0 0 0 0 0 0114.0374223.8378192.8578196.2457228.3532212.5214209.5506192.8647146.6919120.128291.3668114.0374QC'd by XcessBio
Cytotoxic0.1482151.498787Complete curve; high efficacy-6.82920.70.9856.0265207.5252-1.10 1 0 0 0 0 0 0 0 0 051.814202.2596122.7624197.3713167.7834153.3308139.098485.59679.140368.517869.503551.814QC'd by Selleck
Cytotoxic0.093570.605687Complete curve; high efficacy-7.02924.50450.961352.9846123.5901-1.10 1 0 0 0 0 0 0 0 0 041.374115.1832175.7294133.236122.1014112.51554.255357.095263.733753.56750.781741.374QC'd by SynKinase
Cytotoxic0.001087Complete curve; high efficacy-900.957630.251130.2511-1.10 0 0 0 0 0 0 0 0 0 07.7137142.2621159.750441.789140.52422.573521.992937.056330.251115.915614.28657.7137QC'd by Selleck
Cytotoxic0.001087Complete curve; high efficacy-900.935330.652530.6525-1.10 0 0 0 0 0 0 0 0 0 010.0983153.490588.457756.636528.973143.343733.830730.652518.384511.756211.590310.0983QC'd by Selleck
Cytotoxic0.2635171.464186Complete curve; high efficacy-6.57924.95490.90355.2524226.7165-1.10 0 0 0 0 0 0 0 0 0 087.6192224.0953196.7275198.1303295.2794221.4309194.687546.556551.514833.151858.588387.6192QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Free fatty acid receptor 4
External ID: CHEMBL4015237
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593

Target ChEMBL ID: CHEMBL5339
ChEMBL Target Name: G-protein coupled receptor 120
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeActivity Comment
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
ActivityNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4015250
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593
Standard TypeStandard RelationStandard ValueStandard Units
Stability=49%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM1R-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0093104.652788Complete curve; high efficacy-8.02921.96730.994643.2871147.9397-1.10 0 0 0 0 0 0 0 0 0 046.9856151.2515136.3124112.156860.347441.289143.600645.536740.858441.487544.24846.9856QC'd by Cayman
Cytotoxic0.052690.729187Complete curve; high efficacy-7.27921.24750.96949.3002140.0293-1.10 0 0 0 0 0 0 0 0 0 036.2116136.8931136.6639140.7519111.565496.338258.16355.06458.665957.368148.852936.2116QC'd by Selleck
Cytotoxic0.1865111.099886Complete curve; high efficacy-6.72921.55790.959758.0636169.1634-1.10 0 0 0 0 0 0 0 0 0 030.8392165.6134164.7399166.9572172.8379153.7472111.421772.293771.432370.561564.820230.8392QC'd by Tocris
Cytotoxic0.104999.253786Complete curve; high efficacy-6.97923.1320.878851.4415150.6952-1.10 0 0 0 0 0 0 0 0 0 04.3763133.6762159.094152.6324154.4225134.385464.985170.629468.541858.555955.58134.3763QC'd by Selleck
Cytotoxic0.331794.992984Complete curve; high efficacy-6.47920.30.952137.641132.6338-1.10 0 0 0 0 0 0 0 0 0 050.4436114.4568123.9845113.833196.15292.162489.666481.881579.922468.155859.613750.4436QC'd by Tocris
Cytotoxic0.742784.904484Complete curve; high efficacy-6.12922.25260.93345.6644130.5688-1.10 0 0 0 0 0 0 0 0 0 036.4643134.3384115.1991125.3701119.0101144.1666143.817297.989150.782553.051854.389936.4643QC'd by Tocris
Cytotoxic0.833375.35484Complete curve; high efficacy-6.07923.990.961446.5835121.9376-1.10 0 0 0 0 0 0 0 0 0 033.0973124.2208119.0164110.2614120.2463126.3612130.9298108.885950.932550.258656.053633.0973QC'd by Selleck
Cytotoxic0.372288.076284Complete curve; high efficacy-6.42924.44950.970337.6549125.7311-1.10 0 0 0 0 0 0 0 0 0 044.0074106.5992127.2247130.6238138.3415127.8948120.698748.218435.913536.364134.92644.0074QC'd by Selleck
Cytotoxic0.0093130.642584Complete curve; high efficacy-8.02920.90.986724.621155.2635-1.10 0 0 0 0 0 0 0 0 0 018.1076143.3641125.709898.568566.033436.988237.469536.872131.027325.006419.273518.1076QC'd by Toronto Research
Cytotoxic0.468684.349983Complete curve; high efficacy-6.32923.06540.892737.763122.1129-1.10 0 0 0 0 0 0 0 0 0 08.9174100.9718133.1095113.0152128.6977133.2765119.584364.278453.378148.528644.758.9174QC'd by SynKinase
Cytotoxic0.331788.677483Complete curve; high efficacy-6.47921.62590.990934.1483122.8257-1.10 0 0 0 0 0 0 0 0 0 032.8455112.8257122.9968126.477124.3559121.535296.460460.397143.403334.092232.873332.8455QC'd by JohnsHopkins
Cytotoxic0.2957104.439583Complete curve; high efficacy-6.52920.60.963633.4657137.9052-1.10 0 0 0 0 0 0 0 0 0 030.41139.5422127.9789115.7906133.779110.19387.959673.595558.104955.361347.914130.41QC'd by JohnsHopkins
Cytotoxic2.348586.675883Complete curve; high efficacy-5.62924.0950.968453.6121140.2879-1.10 0 0 0 0 0 0 0 0 0 051.2528135.5146146.9511127.3268148.5202130.0159143.2286148.4195122.370157.612755.742751.2528QC'd by LINCS
Cytotoxic0.589978.481583Complete curve; high efficacy-6.229210.96239.6422118.1236-1.10 0 0 0 0 0 0 0 0 0 036.8849113.0988105.5924123.1519126.3882114.847893.448478.396461.99652.62141.616136.8849QC'd by NCGCChem
Cytotoxic1.662685.967283Complete curve; high efficacy-5.77922.47290.929540.7279126.6952-1.10 0 0 0 0 0 0 0 0 0 028.4756118.8121112.7597122.0662124.4452131.3159149.7541122.838280.294449.812550.994128.4756QC'd by Microsource
Cytotoxic0.074390.741383Complete curve; high efficacy-7.12921.96730.946425.6492116.3905-1.10 0 0 0 0 0 0 0 0 0 05.9198106.5785111.2723128.5693109.673979.414437.115833.672241.61829.688719.14745.9198QC'd by Selleck
Cytotoxic0.4176196.850483Complete curve; high efficacy-6.37920.30.9606-31.7676165.0828-1.10 0 0 0 0 0 0 0 0 0 02.8348135.921148.6439123.1507111.473178.544671.308564.760262.7228.685414.04622.8348QC'd by Microsource
Cytotoxic0.525895.995583Complete curve; high efficacy-6.27920.40.975335.9633131.9588-1.10 0 0 0 0 0 0 0 0 0 050.6988124.3759129.0401111.2096110.666498.319199.274582.50577.957559.853253.136550.6988QC'd by Microsource
Cytotoxic0.1865153.297482Complete curve; high efficacy-6.72920.40.9838-19.1976134.0998-1.10 0 0 0 0 0 0 0 0 0 01.5971128.3939102.50195.957690.349376.112759.654643.641425.05494.92791.71.5971QC'd by NCGCChem
Cytotoxic0.4686112.636982Complete curve; high efficacy-6.32920.70.96616.772129.4089-1.10 0 0 0 0 0 0 0 0 0 013.877117.2722122.3984135.2437130.0817105.741580.360967.039351.753440.54130.169413.877QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4015251
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593
Standard TypeStandard RelationStandard ValueStandard Units
Stability=35%
Stability=57%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL1038588
Protocol: N/A
Comment: Journal: Eur. J. Med. Chem.
Year: 2009
Volume: 44
Issue: 10
First Page: 4136
Last Page: 4147
DOI: 10.1016/j.ejmech.2009.05.011

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
43000IC50=43000000nMOutside typical range
31100IC50=31100000nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-mm1s-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.013278.888888Complete curve; high efficacy-7.87923.51170.995147.2347126.1235-1.10 0 0 0 0 0 0 0 0 0 042.2827127.6613122.708120.202461.112651.288545.516147.740746.357847.533948.054342.2827QC'd by SigmaAldrich
Cytotoxic0.018794.499187Complete curve; high efficacy-7.72921.96730.992343.1973137.6963-1.10 0 0 0 0 0 0 0 0 0 047.5181141.319129.8171127.504186.807649.094247.049942.27740.938537.815144.862147.5181QC'd by ACC
Cytotoxic0.525873.986887Complete curve; high efficacy-6.27921.53860.960875.2185149.2053-1.10 0 0 0 0 0 0 0 0 0 066.1566142.7053154.8249147.903146.0134146.4254144.006104.273988.096990.959471.649566.1566QC'd by JohnsHopkins
Cytotoxic0.0059140.454587Complete curve; high efficacy-8.22921.41630.968736.1127176.5672-1.10 0 0 0 0 0 0 0 0 0 010.8624168.6765147.515496.349154.200241.544537.572842.209341.742240.483343.494610.8624QC'd by Cayman
Cytotoxic0.013279.744487Complete curve; high efficacy-7.87920.60.898641.6151121.3595-1.10 0 0 0 0 0 0 0 0 0 026.1462113.0499103.137682.203181.485258.693853.314553.669254.537937.118656.47926.1462QC'd by SigmaAldrich
Cytotoxic0.166378.942786Complete curve; high efficacy-6.77923.92950.945949.4968128.4395-1.10 0 0 0 0 0 0 0 0 0 039.1638119.9619118.7114121.8873145.134135.660277.501949.371642.704855.488760.915639.1638QC'd by SynKinase
Cytotoxic0.117799.522986Complete curve; high efficacy-6.92920.50.978453.5004153.0233-1.10 0 0 0 0 0 0 0 0 0 054.2364146.2425146.4285127.5196118.6607112.3725102.003786.351770.597462.725470.168354.2364QC'd by Selleck
Cytotoxic0.234879.922286Complete curve; high efficacy-6.62921.46410.979158.9416138.8638-1.10 0 0 0 0 0 0 0 0 0 062.4132143.4278135.9313129.1028144.3799129.2524105.203973.502570.461953.739757.639662.4132QC'd by BIOMOL
Cytotoxic0.0187133.261986Complete curve; high efficacy-7.72920.60.944135.7906169.0525-1.10 0 0 0 0 0 0 0 0 0 027.5582156.1894139.4018135.437491.108661.224166.094967.717153.596142.584230.965227.5582QC'd by Toronto Research
Cytotoxic0.029679.81285Complete curve; high efficacy-7.52923.1320.836730.4945110.3065-1.10 0 0 0 0 0 0 0 0 0 0-0.421991.4427118.502121.280287.417839.0630.378326.00428.811631.88664.9696-0.4219QC'd by ChemAxon
Cytotoxic0.468672.558485Complete curve; high efficacy-6.32921.47810.89858.4082130.9666-1.10 0 0 0 0 0 0 0 0 0 036.5241121.5091138.67123.1995141.6082124.8321119.084385.203570.543862.760678.203936.5241QC'd by SIGMA
Cytotoxic0.574989.317185Complete curve; high efficacy-6.24043.51170.938153.4216142.7387-1.10 0 0 0 0 0 0 0 0 0 042.1397122.2594133.5752138.8262155.9137150.9759155.3277133.833270.150756.140464.45942.1397QC'd by Selleck
Cytotoxic0.104990.112685Complete curve; high efficacy-6.97921.10.9642.4601132.5727-1.10 0 0 0 0 0 0 0 0 0 048.0597134.7202138.2028122.4795111.2704105.46677.884945.23345.497230.823755.272548.0597QC'd by Tocris
Cytotoxic0.041880.357885Complete curve; high efficacy-7.37920.60.851133.6315113.9892-1.10 0 0 0 0 0 0 0 0 0 011.0841101.2736106.771596.716682.13570.480940.105551.505451.453654.137541.943611.0841QC'd by Microsource
Cytotoxic0.661994.77385Complete curve; high efficacy-6.17921.47810.980353.7716148.5446-1.10 0 0 0 0 0 0 0 0 0 055.0629148.0214138.5482154.1536143.4321157.4598136.588499.863477.243358.434452.819555.0629QC'd by Selleck
Cytotoxic0.2093116.503485Complete curve; high efficacy-6.67921.3310.904546.5044163.0078-1.10 0 0 0 0 0 0 0 0 0 013.0869143.6239161.4686168.1578159.9801164.488797.670664.784668.491371.476350.62513.0869QC'd by Selleck
Cytotoxic0.295796.448284Complete curve; high efficacy-6.52921.82650.979336.1131132.5613-1.10 0 0 0 0 0 0 0 0 0 027.7595137.6757133.1247125.0579141.4133118.8792106.669652.975840.619540.756544.348527.7595QC'd by BIOMOL
Cytotoxic0.372296.5784Complete curve; high efficacy-6.42921.47870.980840.3311136.901-1.10 0 0 0 0 0 0 0 0 0 041.4841141.6948138.6029123.988145.2114122.9084114.816475.052646.365545.832838.682941.4841QC'd by BIOMOL
Cytotoxic0.013299.542284Complete curve; high efficacy-7.87920.50.859825.2368124.779-1.10 0 0 0 0 0 0 0 0 0 033.6254113.8403106.930467.885457.737956.717356.006446.273443.48929.15714.453233.6254QC'd by NCGCChem
Cytotoxic2.093175.060284Complete curve; high efficacy-5.67924.95490.948360.3489135.4091-1.10 0 0 0 0 0 0 0 0 0 060.7384119.1757138.3496139.0789136.1425149.2097137.4143127.2154116.932554.542266.866760.7384QC'd by ChemAxon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4015248
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593
Standard TypeStandard Text ValueStandard Units
StabilityStable%
StabilityStable%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS-28PE-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Inconclusive2.093152.377810Complete curve; partial efficacy; poor fit-5.67921.210.8868207.717155.33921.40 0 0 0 1 0 0 0 0 0 1147.1164.4833155.0085150.5868148.3401116.6514156.9711173.7174168.6881199.2135202.8962147.1QC'd by Microsource
Inconclusive0.005712.519610Complete curve; partial efficacy; poor fit-8.24044.95490.312131.5823119.06271.40 0 0 0 0 0 0 0 0 0 1127.1473120.0823122.1295115.8993137.6706122.1335127.163123.7971150.7316133.1825125.6113127.1473QC'd by SIGMA
Inconclusive0.00192110Complete curve; partial efficacy; poor fit-8.72921.10.8356134.2114113.21141.40 0 0 0 0 0 0 0 0 0 1119.1302117.2114127.4759130.4637129.9536131.9164134.6866133.4534131.6405137.8111137.2931119.1302QC'd by Pharmeks
Inconclusive0.066221.510Complete curve; partial efficacy; poor fit-7.17921.96730.9617136.1907114.69071.40 0 0 0 0 0 0 0 0 0 0137.9456114.6907115.3457114.9342114.9118125.4369132.2852136.9063134.4597139.5384132.1379137.9456QC'd by Sequoia
Inconclusive0.148221.099810Complete curve; partial efficacy; poor fit-6.82920.80.8442149.6919128.59211.40 0 0 0 0 0 0 0 0 0 0151.9116131.6919128.2754129.76129.967133.7039147.8377137.7359147.2819148.9579147.0679151.9116QC'd by Tocris
Inconclusive0.083330.510Complete curve; partial efficacy; poor fit-7.07920.30.9065152.817122.3171.40 0 0 0 0 0 0 0 0 0 0149.8479126.317131.9239133.2597133.1414138.2988138.8257144.3744142.6826141.1244150.4849149.8479QC'd by APAC
Inconclusive0.0032310Complete curve; partial efficacy; poor fit-8.52920.70.9042116.673193.67311.40 0 0 0 0 0 0 0 0 0 0115.023597.6731106.1567108.9656113.5207111.3295114.3155115.674116.5526117.8964119.9437115.0235QC'd by SigmaAldrich
Inconclusive0.001925.510Complete curve; partial efficacy-8.72921.55790.7725134.9997109.49971.20 0 0 0 0 0 0 0 0 0 0138.6831113.4997125.8748129.6566135.9028133.275139.8144131.171127.5454138.1274135.3784138.6831QC'd by SigmaAldrich
Inactive0-5.02920.80.4643103.7426121.954440 0 0 0 0 0 0 0 0 0 0106.6946111.4544125.2432128.5053127.1929113.4715124.3917121.815114.296116.6521111.8738106.6946QC'd by BIOMOL
Inactive04125.6815122.8795130.2888125.1136125.6652130.3074128.7078129.9384126.7494127.6785129.7132125.6815QC'd by BIOMOL
Inactive04136.2326163.4273142.6615146.3348166.6634150.6103158.3404165.0578162.7658150.3198139.9664136.2326QC'd by BIOMOL
Inactive0-7.37920.80.6066126.3684141.901940 0 0 0 0 0 0 0 0 0 0126.5818144.4019133.558143.8479137.0521128.3337135.1801122.2906134.5644123.4653125.8628126.5818QC'd by BIOMOL
Inactive0-4.92924.95490.7372120.4574134.013840 0 0 0 0 0 0 0 0 0 0120.7168134.5138134.0383138.0285138.2397129.2732130.6596135.9635130.2877134.4747123.0085120.7168QC'd by BIOMOL
Inactive0-6.87923.1320.4017111.9315106.526540 0 0 0 0 0 0 0 0 0 1105.5505105.9315109.5176101.4274110.4744106.5334110.4821115.977107.3312113.281111.1989105.5505QC'd by BIOMOL
Inactive0-4.67924.50450.6481132.5399143.83940 0 0 0 0 0 0 0 0 0 0132.7564143.839141.5609139.3268147.1235144.923140.6337146.4103146.2306145.3224141.4193132.7564QC'd by BIOMOL
Inactive0-4.57920.90.6882159.3525129.352540 0 0 0 0 0 0 0 0 0 0151.1525125.3525127.8444130.5681128.6677140.8596130.7582127.8002131.1106130.9549139.8805151.1525QC'd by BIOMOL
Inactive0-6.97920.40.9481115.525797.048340 0 0 0 0 0 0 0 0 0 0114.535699.525798.7112102.3247103.7206107.7162106.0966108.4061110.7209110.6769114.5412114.5356QC'd by BIOMOL
Inactive0-5.17922.40640.5201113.1718140.123540 0 0 0 0 0 0 0 0 0 0115.0077144.1235142.7954132.4372151.4407117.6804133.3272147.8257140.0962131.6466114.5804115.0077QC'd by BIOMOL
Inactive04129.9994131.8514126.6454132.768130.4791123.0823132.8921130.718134.7376125.1039126.4003129.9994QC'd by BIOMOL
Inactive0-5.97923.51170.87899.8725117.809540 0 0 0 0 0 0 0 0 0 0106.7355120.8095114.2948118.894116.6347119.8485116.4782116.0413102.243498.24195.0287106.7355QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4015249
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593
Standard TypeStandard RelationStandard ValueStandard Units
Stability=63%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-LP_1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010587.390386Complete curve; high efficacy-7.97921.55790.989332.5525119.9428-1.10 0 0 0 0 0 0 0 0 0 032.5973120.122108.670192.358749.68844.854932.131433.603134.763228.3332.048332.5973QC'd by Tocris
Cytotoxic0.008376.084786Complete curve; high efficacy-8.07922.40640.978834.0695110.1542-1.10 0 0 0 0 0 0 0 0 0 024.173108.041107.758381.913639.516542.556837.70132.500733.657937.059831.016624.173QC'd by Toronto Research
Cytotoxic0.018777.542886Complete curve; high efficacy-7.72921.78850.962734.3529111.8957-1.10 0 0 0 0 0 0 0 0 0 033.0008112.3533115.065889.919978.411730.490234.730734.354633.092838.520140.803433.0008QC'd by Selleck
Cytotoxic0.05988.700585Complete curve; high efficacy-7.22920.60.969436.3948125.0953-1.10 0 0 0 0 0 0 0 0 0 028.5989117.1885119.5312102.469690.645885.862360.636451.829952.266249.734541.128528.5989QC'd by Selleck
Cytotoxic0.033277.128185Complete curve; high efficacy-7.47920.70.965531.2029108.331-1.10 0 0 0 0 0 0 0 0 0 022.5571101.2018101.265588.845670.184569.842243.682140.23739.306637.25836.404722.5571QC'd by Selleck
Cytotoxic0.018779.858785Complete curve; high efficacy-7.72923.51170.958432.0611111.9199-1.10 0 0 0 0 0 0 0 0 0 013.2093112.4294107.1384115.125260.413141.924537.316331.47637.27735.928730.843213.2093QC'd by Cayman
Cytotoxic0.093586.449185Complete curve; high efficacy-7.02921.10.944937.248123.6972-1.10 0 0 0 0 0 0 0 0 0 026.2605129.9165117.2503108.9438120.53891.515551.119756.159151.860742.057332.899826.2605QC'd by Tocris
Cytotoxic0.020993.129385Complete curve; high efficacy-7.67921.46410.961833.1188126.2481-1.10 0 0 0 0 0 0 0 0 0 022.4794117.474125.7046121.844767.966156.055641.326142.215733.927132.351729.697222.4794QC'd by Selleck
Cytotoxic0.0332100.48585Complete curve; high efficacy-7.479210.970731.2298131.7149-1.10 0 0 0 0 0 0 0 0 0 025.5067135.567116.3384110.9262105.252653.915347.874942.057435.306632.7930.969525.5067QC'd by SIGMA
Cytotoxic0.029693.442184Complete curve; high efficacy-7.52923.92950.974823.6719117.114-1.10 0 0 0 0 0 0 0 0 0 025.7428100130.2442120.83397.558327.822521.54819.831323.18926.683424.643725.7428QC'd by SigmaAldrich
Cytotoxic0.372276.55184Complete curve; high efficacy-6.42921.210.930841.5458118.0968-1.10 0 0 0 0 0 0 0 0 0 026.8735126.0105102.8329112.503124.3981120.178987.830470.201454.107949.917250.88526.8735QC'd by ChemieTek
Cytotoxic0.132181.241484Complete curve; high efficacy-6.87924.95490.942234.404115.6454-1.10 0 0 0 0 0 0 0 0 0 026.3475111.8181103.4247109.6276115.8533135.698144.775439.68148.652328.651829.112426.3475QC'd by Microsource
Cytotoxic0.148282.701584Complete curve; high efficacy-6.82923.92950.980732.7831115.4845-1.10 0 0 0 0 0 0 0 0 0 029.9601112.1327117.5155121.9023104.2805119.069555.455342.556433.026630.915628.938629.9601QC'd by Selleck
Cytotoxic0.05976.700284Complete curve; high efficacy-7.22921.50950.976329.9655106.6658-1.10 0 0 0 0 0 0 0 0 0 021.9818106.9151109.4753101.075790.329271.880834.561430.807840.756634.092828.492121.9818QC'd by SantaCruz Bio
Cytotoxic0.020988.802383Complete curve; high efficacy-7.67923.51170.951216.2799105.0822-1.10 0 0 0 0 0 0 0 0 0 03.7081100.414107.4471102.660964.97134.98339.840114.997917.73926.496734.02243.7081QC'd by SIGMA
Cytotoxic0.041893.574583Complete curve; high efficacy-7.37922.18760.998417.8156111.39-1.10 0 0 0 0 0 0 0 0 0 017.4361109.284114.2073106.670495.671445.860321.91818.883416.506916.328316.984617.4361QC'd by ACC
Cytotoxic0.083378.232883Complete curve; high efficacy-7.07920.80.905521.999100.2318-1.10 0 0 0 0 0 0 0 0 0 02.109590.1163103.264689.018286.322667.714235.347539.808535.914336.921628.83652.1095QC'd by ChemAxon
Cytotoxic0.074390.137383Complete curve; high efficacy-7.12920.60.939423.0787113.2161-1.10 0 0 0 0 0 0 0 0 0 014.6398104.4157102.1008106.636185.983463.333350.656440.15953.402331.917625.558714.6398QC'd by Axon Medchem
Cytotoxic0.041884.768783Complete curve; high efficacy-7.37921.22210.965421.7645106.5332-1.10 0 0 0 0 0 0 0 0 0 018.8147105.573699.2727109.218868.570462.902925.88328.211225.408922.860621.049818.8147QC'd by Selleck
Cytotoxic0.0469101.067483Complete curve; high efficacy-7.32920.90.956722.9637124.0311-1.10 0 0 0 0 0 0 0 0 0 07.6524111.1073130.7357106.619390.519265.038238.879739.549834.132432.242524.93497.6524QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4015246
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593
Standard TypeStandard Text ValueStandard Units
StabilityStable%
StabilityStable%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MOLP-8-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.2348112.884984Complete curve; high efficacy-6.62920.40.939237.0886149.9734-1.11 0 0 0 0 0 0 0 0 0 047.4866100.2991140.8419123.7999110.5725117.564587.825378.249885.531267.105248.08847.4866QC'd by SantaCruz Bio
Cytotoxic0.0332135.867784Complete curve; high efficacy-7.47920.40.868624.8504160.7181-1.10 0 0 0 0 0 0 0 0 0 09.5856132.6885149.7338116.748673.778973.989769.730568.018654.415855.950840.44799.5856QC'd by SIGMA
Cytotoxic2.0931100.118383Complete curve; high efficacy-5.67920.40.953450.966151.0844-1.10 0 0 0 0 0 0 0 0 0 067.4421149.8224143.8978144.1774136.6925121.0787121.338115.4935112.696598.792974.828167.4421QC'd by Tocris
Cytotoxic0.0132104.008283Complete curve; high efficacy-7.87921.92820.988715.4484119.4565-1.10 0 0 0 0 0 0 0 0 0 04.6572119.4565113.395898.070346.344719.738622.763617.901420.621915.88212.51264.6572QC'd by Selleck
Cytotoxic0.0235123.025483Complete curve; high efficacy-7.62920.40.833719.8641142.8896-1.10 0 0 0 0 0 0 0 0 0 012.2641131.0145115.543690.295153.905271.215162.338757.160461.969514.810235.382712.2641QC'd by Cayman
Cytotoxic0.209385.298783Complete curve; high efficacy-6.67920.70.933425.0186110.3173-1.10 0 0 0 0 0 0 0 0 0 027.0991109.8173117.737596.065379.189496.830975.536451.699233.826328.186136.413327.0991QC'd by NCGCChem
Cytotoxic3.317381.307483Complete curve; high efficacy-5.47922.33320.931557.6371138.9446-1.10 0 0 0 1 0 0 0 0 0 049.2543138.4338143.9848151.4142126.008995.5126125.5596148.3456124.31378.15369.765749.2543QC'd by Selleck
Cytotoxic0.005936.966482Complete curve; partial efficacy-8.22922.33320.9077119.6572156.6236-1.20 0 0 0 0 0 0 0 0 0 0121.5044156.5384152.389136.5428116.1001121.0618114.6459112.3913119.9242122.9008128.5083121.5044QC'd by Tocris
Cytotoxic0.0235114.209482Complete curve; high efficacy-7.62920.50.976314.7696128.979-1.10 0 0 0 0 0 0 0 0 0 010.4187119.189695.722479.624580.242657.691343.007536.236630.095223.109920.65110.4187QC'd by FLUKA
Cytotoxic3.722180.870382Complete curve; high efficacy-5.42924.95490.903234.983115.8532-1.10 0 0 0 0 0 0 0 0 0 031.7555109.588598.898113.8737107.8306136.1674134.0604103.0938120.4749.927837.402931.7555QC'd by Selleck
Cytotoxic0.093590.511982Complete curve; high efficacy-7.02922.40640.907611.9163102.4282-1.10 0 0 0 0 0 0 0 0 0 012.606679.81796.8282103.1563135.242367.22833.455113.67799.624510.775711.22312.6066QC'd by Selleck
Cytotoxic0.166394.761582Complete curve; high efficacy-6.77922.25260.98616.386111.1475-1.10 0 0 0 0 0 0 0 0 0 013.149108.3556124.8245103.3906106.2074102.246958.785121.215318.077319.677216.032513.149QC'd by Selleck
Cytotoxic0.5258104.154382Complete curve; high efficacy-6.279210.941418.3838122.5381-1.10 0 0 0 0 0 0 0 0 0 011.0314104.3828126.1461116.2417132.0669128.168183.354461.552952.656732.958721.753411.0314QC'd by JohnsHopkins
Cytotoxic0.1321103.787382Complete curve; high efficacy-6.87920.90.96614.4792118.2664-1.10 0 0 0 0 0 0 0 0 0 017.9536125.3305107.6763112.1488100.702673.069975.951528.288418.604519.064616.652717.9536QC'd by Axon Medchem
Cytotoxic0.0132114.512182Complete curve; high efficacy-7.87922.04790.990314.6838129.1959-1.10 0 0 0 0 0 0 0 0 0 013.3585136.7296116.4775107.708242.698923.621911.168115.726818.095413.321414.334613.3585QC'd by ChemieTek
Cytotoxic0.1321156.013482Complete curve; high efficacy-6.87920.40.9789-13.9595142.0539-1.10 0 0 0 0 0 0 0 0 0 02.982129.411119.3857103.9503100.891163.90856.490249.420432.44885.10223.55372.982QC'd by Selleck
Cytotoxic3.722184.036682Complete curve; high efficacy-5.42921.98870.889233.1062117.1428-1.10 0 0 0 0 0 0 0 0 0 022.583104.9664128.4651118.0164124.042993.0546124.0918125.7379103.197156.428452.504522.583QC'd by XcessBio
Cytotoxic1.320784.378182Complete curve; high efficacy-5.87924.44950.910828.6573113.0354-1.10 0 0 0 0 0 0 0 0 0 050.695598.1375111.271125.1555106.5195116.7283107.7109122.303149.824127.93655.97250.6955QC'd by Microsource
Cytotoxic0.525893.379882Complete curve; high efficacy-6.27922.33320.98319.1033112.4831-1.10 0 0 0 0 0 0 0 0 0 016.8591105.468124.7832114.5473109.601102.2654109.906561.363223.850621.146220.522416.8591QC'd by Selleck
Cytotoxic0.052698.055282Complete curve; high efficacy-7.27921.50950.986815.7184113.7736-1.10 0 0 0 0 0 0 0 0 0 012.9644114.8405118.277999.487995.383561.412321.163723.874615.920820.047211.588312.9644QC'd by Axon Medchem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4015247
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2017
Volume: 60
Issue: 9
First Page: 3636
Last Page: 3655
DOI: 10.1021/acs.jmedchem.6b01593
Standard TypeStandard Text ValueStandard Units
StabilityStable%
StabilityStable%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM-M1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010576.742198Complete curve; high efficacy-7.97920.40.8143106.1488182.891-1.10 0 0 0 0 0 0 0 0 0 097.0213175.2098149.2496135.4049151.407123.166130.2765116.1855114.3842112.5027122.711897.0213QC'd by SigmaAldrich
Cytotoxic0.020959.606490Complete curve; high efficacy-7.67922.33320.874365.0446124.6509-1.10 0 0 0 0 0 0 0 0 0 042.5491114.2054125.0887133.638390.399669.076975.433362.892474.984266.982668.241342.5491QC'd by Selleck
Cytotoxic0.018799.387289Complete curve; high efficacy-7.72920.70.980954.5973153.9845-1.10 0 0 0 0 0 0 0 0 0 052144.7606143.678116.218996.581992.313370.116662.478959.112861.584152.567552QC'd by SynKinase
Cytotoxic0.417668.959788Complete curve; high efficacy-6.37923.51170.895189.8298158.7896-1.11 0 0 0 0 0 0 0 0 0 095.9522121.7497145.5234145.5172164.4127183.3401150.4309108.335677.511895.882489.823695.9522QC'd by Axon Medchem
Cytotoxic0.589969.181988Complete curve; high efficacy-6.22923.990.762995.3406164.5224-1.10 0 0 0 0 0 0 0 0 0 0109.573149.3937173.4718129.8513191.2497150.3213190.3378133.864783.187296.413691.5262109.573QC'd by Selleck
Cytotoxic0.0743107.054887Complete curve; high efficacy-7.12920.80.984554.8206161.8754-1.10 0 0 0 0 0 0 0 0 0 057.9387151.8563163.9611143.7973136.7288112.919683.16276.873368.177453.226952.637857.9387QC'd by Selleck
Cytotoxic0.148283.542787Complete curve; high efficacy-6.82924.44950.95860.4745144.0173-1.10 0 0 0 0 0 0 0 0 0 069.2734130.5346130.6652147.3751155.1668153.941881.695563.29659.260855.616355.513469.2734QC'd by Selleck
Cytotoxic1.177117.97687Complete curve; high efficacy-5.92920.30.8809103.6252221.6012-1.10 0 0 0 0 0 0 0 0 0 0124.3584204.1012213.7323210.6584195.2614187.4914165.4267159.6533180.5857156.7486132.0473124.3584QC'd by Microsource
Cytotoxic0.005986.11287Complete curve; high efficacy-8.22923.92950.940835.788121.9-1.10 0 0 0 0 0 0 0 0 0 016.9728119.2292123.80460.906149.612339.010736.652141.355244.341829.622331.979616.9728QC'd by Selleck
Cytotoxic0.661977.798687Complete curve; high efficacy-6.17921.46410.905587.7533165.5518-1.11 0 0 0 0 0 0 0 0 0 081.2811136.4201144.0668155.7612179.4399178.5787159.509126.3915103.3855100.192987.184981.2811QC'd by Selleck
Cytotoxic0.132189.890486Complete curve; high efficacy-6.87920.80.95149.0129138.9033-1.10 0 0 0 0 0 0 0 0 0 040.8231126.0203148.1813124.8099131.8805103.371579.016473.44667.02155.440553.384540.8231QC'd by Toronto Research
Cytotoxic0.4176102.258786Complete curve; high efficacy-6.37920.90.955864.4239166.6826-1.10 0 0 0 0 0 0 0 0 0 062.0508169.9186163.4857169.1241146.548155.8497143.523295.509585.826689.782263.021662.0508QC'd by JohnsHopkins
Cytotoxic1.481876.048286Complete curve; high efficacy-5.82921.64360.961186.8287162.8769-1.11 0 0 0 0 0 0 0 0 0 082.8262126.6031167.7674148.1546170.4052160.7596163.2256153.9322115.8888102.739187.384382.8262QC'd by Microsource
Cytotoxic0.93570.299185Complete curve; high efficacy-6.02921.10.944964.9721135.2712-1.10 0 0 0 0 0 0 0 0 0 054.1264136.8416133.7919124.0367139.8306136.3935126.542109.431383.56279.460279.257954.1264QC'd by Selleck
Cytotoxic0.1049113.233785Complete curve; high efficacy-6.97921.10.946739.4295152.6631-1.10 0 0 0 0 0 0 0 0 0 032.5405140.1803150.363153.1014157.369294.872271.375973.052248.593136.378239.149432.5405QC'd by Selleck
Cytotoxic0.0166145.913585Complete curve; high efficacy-7.77920.70.982429.6583175.5718-1.10 0 0 0 0 0 0 0 0 0 034.6378162.9357140.528136.147383.994477.337854.505136.927832.978933.61429.924334.6378QC'd by Selleck
Cytotoxic0.742787.807885Complete curve; high efficacy-6.12921.82650.8961.3799149.1877-1.10 0 0 0 0 0 0 0 0 0 043.6517125.4482151.4934151.5693138.7177162.0934165.3929104.484285.588670.237469.183243.6517QC'd by SynKinase
Cytotoxic0.002672.145785Complete curve; high efficacy-8.57921.22210.943724.741896.8875-1.10 0 0 0 0 0 0 0 0 0 016.212489.740360.566940.694133.868835.347627.530728.413321.997521.291722.494316.2124QC'd by Selleck
Cytotoxic0.935100.642185Complete curve; high efficacy-6.02920.70.92361.7833162.4254-1.10 0 0 0 0 0 0 0 0 0 057.3523168.1282144.1115151.7026171.4086158.4019133.5552112.5955103.328285.466988.368357.3523QC'd by Selleck
Cytotoxic2.635188.832385Complete curve; high efficacy-5.57920.80.900992.8317181.664-1.10 0 0 0 0 0 0 0 0 0 098.7032172.664175.775187.4451189.4966178.714170.8024149.3555161.8016111.5356120.77798.7032QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OCI_MY1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.093583.133787Complete curve; high efficacy-7.02920.60.973252.9139136.0477-1.10 0 0 0 0 0 0 0 0 0 054.7559135.1374118.648125.1116118.336796.366979.597475.149571.390359.692254.239654.7559QC'd by Selleck
Cytotoxic0.0332111.725186Complete curve; high efficacy-7.47920.30.926242.1257153.8508-1.10 0 0 0 0 0 0 0 0 0 051.7825144.6362112.8549103.828595.219288.923187.26580.966170.718165.599553.464751.7825QC'd by Cayman
Cytotoxic0.041882.751485Complete curve; high efficacy-7.37920.50.975933.8657116.617-1.10 0 0 0 0 0 0 0 0 0 028.5726108.62298.686993.798783.828667.416856.438356.969748.110946.342837.744328.5726QC'd by SynKinase
Cytotoxic0.029692.090785Complete curve; high efficacy-7.52920.50.938335.476127.5667-1.10 0 0 0 0 0 0 0 0 0 029.5556114.1336120.894588.726181.575576.202554.682455.648457.304545.91137.137429.5556QC'd by SynKinase
Cytotoxic0.186570.386984Complete curve; high efficacy-6.72922.72020.976138.0815108.4684-1.10 0 0 0 0 0 0 0 0 0 047.1917108.8739108.2531101.5408112.4163108.138570.335743.665234.539228.36141.664847.1917QC'd by JohnsHopkins
Cytotoxic0.417671.667384Complete curve; high efficacy-6.37922.40640.947943.4067115.074-1.10 0 0 0 0 0 0 0 0 0 033.3089105.574126.981118.3238117.612103.7019109.683463.443852.586453.630639.122233.3089QC'd by Selleck
Cytotoxic0.1049108.159184Complete curve; high efficacy-6.97920.30.95531.5875139.7466-1.10 0 0 0 0 0 0 0 0 0 043.3364131.0144114.5692101.756397.195681.028979.285179.03469.839955.06552.703143.3364QC'd by SynKinase
Cytotoxic0.0166112.88483Complete curve; high efficacy-7.77922.72020.988916.1533129.0373-1.10 0 0 0 0 0 0 0 0 0 013.2676116.3272134.3166126.014155.794523.838515.933916.952314.530314.265815.832113.2676QC'd by SIGMA
Cytotoxic0.468694.725883Complete curve; high efficacy-6.32920.60.955729.0284123.7542-1.10 0 0 0 0 0 0 0 0 0 035.6827133.5399103.9822117.9539112.0859105.55983.299274.084264.511341.029741.637235.6827QC'd by Selleck
Cytotoxic0.2635100.875583Complete curve; high efficacy-6.57920.90.896925.7615126.637-1.10 0 0 0 0 0 0 0 0 0 04.542104.9981131.3946122.3505135.6872112.0566.048557.839653.797641.533237.99754.542QC'd by ChemAxon
Cytotoxic0.0469103.265883Complete curve; high efficacy-7.32921.47870.994524.4756127.7413-1.10 0 0 0 0 0 0 0 0 0 022.0142133.8948120.7681119.4508105.615665.752534.739831.818124.476924.170924.920822.0142QC'd by Selleck
Cytotoxic0.468692.471283Complete curve; high efficacy-6.32922.33320.97228.9592121.4304-1.10 0 0 0 0 0 0 0 0 0 029.8907112.9759141.5986120.5517113.8929115.8225112.497662.870633.523828.959228.871129.8907QC'd by Selleck
Cytotoxic0.234889.204483Complete curve; high efficacy-6.62921.46410.977529.1453118.3497-1.10 0 0 0 0 0 0 0 0 0 030.577122.3185120.0124103.9641116.9025116.682575.578553.39729.776427.630331.59430.577QC'd by Selleck
Cytotoxic2.635188.363983Complete curve; high efficacy-5.579210.833353.4354141.7993-1.10 0 0 0 0 0 0 0 0 0 069.1826150.707126.8073140.1173122.6532128.5218127.1755136.3873123.344463.498261.630569.1826QC'd by Chemscene
Cytotoxic1.04994.696982Complete curve; high efficacy-5.97921.92820.986426.5166121.2135-1.10 0 0 0 0 0 0 0 0 0 022.4036111.8163115.5011118.7274126.8177125.7155124.411199.239253.489634.159726.65422.4036QC'd by BIOMOL
Cytotoxic0.132181.439182Complete curve; high efficacy-6.879210.970513.202594.6416-1.10 0 0 0 0 0 0 0 0 0 06.269984.6416100.214488.005489.829466.870145.105225.58927.265521.16810.12696.2699QC'd by Selleck
Cytotoxic0.083392.852382Complete curve; high efficacy-7.07920.40.970612.2421105.0944-1.10 0 0 0 0 0 0 0 0 0 015.231897.301484.070587.11564.466159.841648.860238.500140.277931.426921.966115.2318QC'd by Selleck
Cytotoxic0.023580.806982Complete curve; high efficacy-7.62920.60.988914.690995.4978-1.10 0 0 0 0 0 0 0 0 0 011.797688.131284.02266.582754.926541.216133.27229.074823.708316.203515.847511.7976QC'd by Tocris
Cytotoxic0.001259.123982Complete curve; partial efficacy-8.92924.95490.858799.4449158.5687-1.20 0 0 0 0 0 0 0 0 0 0103.2631152.614894.492295.000194.342694.4109100.4664111.3588107.5709103.868592.1541103.2631QC'd by Selleck
Cytotoxic0.417694.690582Complete curve; high efficacy-6.37922.18760.986124.3029118.9934-1.10 0 0 0 0 0 0 0 0 0 021.4583113.0531121.9635115.8336128.0296109.3466109.274655.291834.103826.512620.023521.4583QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_NCIH929-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.148296.190585Complete curve; high efficacy-6.82923.92950.992444.5048140.6953-1.10 0 0 0 0 0 0 0 0 0 037.5464136.9515141.9942144.5132137.0086139.274769.470850.205143.474741.413450.930437.5464QC'd by JohnsHopkins
Cytotoxic0.012983.536684Complete curve; high efficacy-7.89041.47870.997823.8147107.3513-1.10 0 0 0 0 0 0 0 0 0 023.9151110.1823102.343496.995170.752740.620228.6625.881524.655321.871925.213523.9151QC'd by Chemscene
Cytotoxic0.023592.464784Complete curve; high efficacy-7.62921.96730.956723.2254115.6902-1.10 0 0 0 0 0 0 0 0 0 04.0573111.7434116.8232109.391975.447232.990933.705930.026330.264932.170612.76854.0573QC'd by ChemieTek
Cytotoxic0.288175.880584Complete curve; high efficacy-6.54041.82650.968341.6685117.5491-1.10 0 0 0 0 0 0 0 0 0 036.3204119.5479107.4971113.5971126.3084112.3175118.484679.974545.966145.122348.307136.3204QC'd by Selleck
Cytotoxic0.295781.009684Complete curve; high efficacy-6.52923.19250.926140.4734121.483-1.10 0 0 0 0 0 0 0 0 0 011.322115.4342118.2478121.3497132.2979117.0883107.092749.913546.654851.648750.637411.322QC'd by Prestwick Chemical; Inc.
Cytotoxic0.2635116.509584Complete curve; high efficacy-6.57920.60.970641.249157.7585-1.10 0 0 0 0 0 0 0 0 0 040.8193148.2389152.8144145.5181150.8832117.900795.735582.368280.769561.721251.108540.8193QC'd by Toronto Research
Cytotoxic0.052688.20883Complete curve; high efficacy-7.27921.28760.994223.4223111.6302-1.10 0 0 0 0 0 0 0 0 0 017.5003110.0308111.5061103.845494.601259.384438.839430.849224.832526.413122.221717.5003QC'd by LC Labs
Cytotoxic0.052675.902483Complete curve; high efficacy-7.27922.04790.973721.174997.0774-1.10 0 0 0 0 0 0 0 0 0 018.3476101.803486.025499.482590.080350.384429.228830.857823.374816.245614.543118.3476QC'd by Tocris
Cytotoxic0.052679.925683Complete curve; high efficacy-7.27921.37230.966323.9977103.9232-1.10 0 0 0 0 0 0 0 0 0 017.613998.4232100.1087114.286377.500461.650832.015431.605425.732323.840827.908417.6139QC'd by SynKinase
Cytotoxic0.020990.480783Complete curve; high efficacy-7.67920.90.977517.1515107.6322-1.10 0 0 0 0 0 0 0 0 0 06.471996.9766103.361585.574958.317441.067631.175422.007623.02321.414419.28116.4719QC'd by Selleck
Cytotoxic0.005393.642383Complete curve; high efficacy-8.279210.969714.5291108.1714-1.10 0 0 0 0 0 0 0 0 0 08.149699.284981.998249.133631.068631.287422.589621.209613.435211.247510.25858.1496QC'd by SynKinase
Cytotoxic0.014894.690583Complete curve; high efficacy-7.82921.17050.98217.423112.1135-1.10 0 0 0 0 0 0 0 0 0 012.0947103.9614109.053682.852955.000727.887130.356624.600918.123514.68813.793112.0947QC'd by SynKinase
Cytotoxic0.093596.642483Complete curve; high efficacy-7.02921.66040.992224.5734121.2158-1.10 0 0 0 0 0 0 0 0 0 025.6091121.7166119.6038122.5533110.023190.71841.660937.931622.388222.677922.400325.6091QC'd by Selleck
Cytotoxic0.046982.967883Complete curve; high efficacy-7.32924.95490.917922.6763105.644-1.10 0 0 0 0 0 0 0 0 0 02.6388101.9106107.1814103.9277109.288434.581138.965938.548133.351423.30352.61952.6388QC'd by NCI
Cytotoxic0.0296105.787183Complete curve; high efficacy-7.52920.50.883422.0136127.8007-1.10 0 0 0 0 0 0 0 0 0 04.7056117.0952117.3948102.779158.640855.617851.251852.864946.062539.792825.44594.7056QC'd by Selleck
Cytotoxic0.0209126.334483Complete curve; high efficacy-7.67920.80.98917.1119143.4463-1.10 0 0 0 0 0 0 0 0 0 016.0678134.7593122.167111.586876.247354.666237.345223.48931.102310.658718.953916.0678QC'd by Tocris
Cytotoxic0.0074100.270383Complete curve; high efficacy-8.12922.04790.993616.8213117.0916-1.10 0 0 0 0 0 0 0 0 0 023.4575117.6101105.197473.040125.850513.91814.847215.041116.016216.504218.359623.4575QC'd by Selleck
Cytotoxic0.0235108.888982Complete curve; high efficacy-7.62920.70.99411.7255120.6144-1.10 0 0 0 0 0 0 0 0 0 013.4791114.531297.322186.143674.13546.996429.785423.38115.47313.144913.473313.4791QC'd by BIOMOL
Cytotoxic0.0235110.59682Complete curve; high efficacy-7.62921.62660.976412.0566122.6526-1.10 0 0 0 0 0 0 0 0 0 012.2889128.4612120.246294.57586.24920.741516.111913.685812.951413.59113.568112.2889QC'd by FLUKA
Cytotoxic0.041884.248182Complete curve; high efficacy-7.37920.80.942513.632697.8807-1.10 0 0 0 0 0 0 0 0 0 06.907782.5934102.65586.90856441.11432.79328.119227.818519.73737.48046.9077QC'd by Otava
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ovca-p5-p6-adhesion
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Cells; 4 uL; primary human omental fibroblast, black, clear bottom, low base, 1536-well Aurora assay plate.
2; Incubation; 48 hr; 37C.
3; Cells; 3 uL; 1,200 SKOV3ip1-GFP cells.
4; Compounds; 23nL; acoustic dispenser.
5; Incubation; 2 hr; room temperature.
6; Incubation; 16 hr; 37C.
7; Wash; 5 uL; 1x PBS.
8; Fixing; 5 uL; 4% paraformaldehyde (PFA).
9; Incubation; 15 min; room temperature
10; Wash, 5 uL; 1x PBS.
11; Detection; Fluorescence, excitation filter 488 nm, emission filter 509 nm.

NOTES (numbers refer to Sequence numbers above)
1. For the 1,536-well format, 40 primary human omental fibroblasts and 400 mesothelial cells were seeded with 0.02 mug fibronectin and 0.02 mug collagen type I in 4 muL of growth media (2.3 mm2; Supplementary Fig. S1A).
2. Assay plates were incubated for 48 hours at 37 C.
3. After incubation, 1,200 SKOV3ip1-GFP were seeded in 3 muL of serum-free media (growth media minus FBS) on top of primary human omental cells.
4. Compounds or controls were added to each well immediately after the addition of the cancer cells. Compounds were screened in four doses (0.36-46 mumol/L), and the plates contained the positive control (Tomatine) in eight doses (0.035-75 mumol/L) and DMSO (equal volume controls)
5 - 6. The plates were incubated at room temperature for 2 hours and then at 37 degrees C for 16 hours.
7 - 10. Following incubation, the media were aspirated and each well washed with PBS (5 muL) and then fixed with 4% paraformaldehyde (PFA; 5 muL). After 15 minutes, the PFA solution was aspirated, PBS (5 muL) was added.
11. The number of GFP-labeled cells analyzed using a fluorescent cytometer TTP LabTech Acumen eX3 using 488 nm excitation filter and 509 nm emission filter. Data was normalized to the DMSO treated for negative and Tomatine treated wells for positive control.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.

Yasgar A, Shinn P, Jadhav A, Auld DS, Michael S, Zheng W, Austin CP, Inglese J and Simeonov A, Compound Management for Quantitative High-Throughput Screening. J. Assoc. Lab. Auto., 2008, 13: 79-89. doi: 10.1016/j.jala.2007.12.004.
Comment: Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.347 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.717 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.13 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Inactive0-4.44.95490.7-26.5489-2.540 0 0 0-18.7908-9.95531.45561.5083-18.7908QC'd by Sytravon
Inactive0-6.34.95490.83720.73351340 0 0 03.878311.00870-1.47213.8783QC'd by Sytravon
Inactive000400-7.076700QC'd by Sytravon
Inactive0-6.34.95490.42262.5-6.053240 0 0 1-1.1886-4.62777.6987-2.282-1.1886QC'd by Sytravon
Inactive0-4.854.0950.9177-14.9072340 0 0 0-14.08935.888400-14.0893QC'd by Sytravon
Inactive0-4.454.95490.95657-5.210640 0 0 04.4674-6.4255-3.9724-5.77644.4674QC'd by Sytravon
Inactive00045.1862-0.56328.26719.24945.1862QC'd by Sytravon
Inactive0-6.34.95490.6755-15.57673.540 0 0 100-21.7306-9.31520QC'd by Sytravon
Inactive0-4.454.95490.6676-12.8912340 0 0 0-9.4927009.4652-9.4927QC'd by Sytravon
Inactive0-6.34.95490.3745-10.57291440 0 0 14.139610.0525-25.89414.78664.1396QC'd by Sytravon
Inactive000402.67112.75333.70280QC'd by Sytravon
Inactive0004-3.6287-7.1208-7.42331.4494-3.6287QC'd by Sytravon
Inactive0-5.354.95490.728610.5-0.471540 0 0 08.0023.2258-4.559613.14728.002QC'd by Sytravon
Inactive0-5.752.33320.9993-13.324715.540 0 0 114.874814.90020-12.770614.8748QC'd by Sytravon
Inactive0-5.44.95490.79279-1.106240 0 0 05.94010.6656-3.005211.92895.9401QC'd by Sytravon
Inactive00042.60190002.6019QC'd by Sytravon
Inactive00043.4483-2.3916-0.30492.69873.4483QC'd by Sytravon
Inactive00040-0.59793.04882.0990QC'd by Sytravon
Inactive00044.38879.71611.432913.49334.3887QC'd by Sytravon
Inactive000400-6.89300QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL1038589
Protocol: N/A
Comment: Journal: Eur. J. Med. Chem.
Year: 2009
Volume: 44
Issue: 10
First Page: 4136
Last Page: 4147
DOI: 10.1016/j.ejmech.2009.05.011

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
32500IC50=32500000nMOutside typical range
17000IC50=17000000nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1038590
Protocol: N/A
Comment: Journal: Eur. J. Med. Chem.
Year: 2009
Volume: 44
Issue: 10
First Page: 4136
Last Page: 4147
DOI: 10.1016/j.ejmech.2009.05.011
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
45900IC50=45900000nMOutside typical range
36000IC50=36000000nMOutside typical range
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23209 靶标:N/A
External ID: UIHTS20180925
Protocol: Assay overview:
The purpose of this assay is to identify test compounds that differentially kill either epithelial cells or mesenchymal cells, critical components of EMT. The PC-3E+ and TEM4-18 cell lines, characterized as epithelial cells and mesenchymal cells respectively, were established in Henry Lab (Ref 1). For potential discriminative modulators of EMT, the two cells lines were labeled with GFP and mCherry respectively, and co-cultured together to eliminate those hits that non-discriminatingly kill both epithelial cells and mesenchymal cells by cytotoxicity irrelevant to the EMT properties.
Protocol for the EMT project:
The primary screening data were generated as described in HTS assay protocol table (Ref 2).

Table 1: HTS assay protocol table
Step Parameter Value Description
1. Plate cells 200 uL By MultiFlo. PC3E GFP 2,000 cells/ well and TEM418 mCherry 2,000 cells/well (1:1). Overnight incubation
2. Remove media Flip the plate
3. Add fresh media 150 uL By MultiFlo
4. Controls 200 uL C01-H01, C12 -H12, Hygromycin dose response from H to C were positive control. Wells A01, B01, A12 and B12 were negative control
5. Library 50 uL MSSP library 1 uM final from middle plate in full media
6. Incubation 72 hrs 37 C and 5% CO2
7. Assay readout GFP and mCherry channel imaging Perkin Elmer Operetta high content imaging system, with Harmony image analysis software.
8. Image analysis Green cells and Read cells counting Normalized to the average cell number of well B1 and B12 (no inhibition of cell viability) controls on each plate to get relative cell viability for each well.
9. Hit selection 11 hits The hit criteria for preferential cell killing are compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal
0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing OR Greencells_Normalized is
lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent
by itself for Green cell killing.

The primary screening data (imaging data) were translated into Green or Red cell numbers in each well in the data file.
Comment: Preferential killing compounds are considered as active hits (score of 100) when meeting one of two groups of criteria:

1. Compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal 0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing.

OR

2. Greencells_Normalized is lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent by itself for Green cell killing.
No. of GreenCellsNo. of RedCellsGreenCells_NormalizedRedCells_NormalizedRedCells/GreenCells_Normalized
178911800.881.081.22
196110810.970.991.02
187612910.931.181.27
224410941.1110.9
227512101.121.110.98
199513980.981.281.3
212312931.051.181.13
228112271.131.121
196410900.9711.03
211012951.041.181.14
234213611.161.241.08
201413160.991.21.21
2021127011.161.16
216012871.071.181.1
2022119711.091.1
179810820.890.991.11
193811991.081.060.98
200012601.121.110.99
197112011.11.060.96
210011301.1710.85
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303805
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-11.52%Outside typical range
Inhibition=5.09%
Inhibition=-1.71%
Inhibition=3.69%
Inhibition=22.47%
Inhibition=8.51%
Inhibition=-6.86%
Inhibition=-6.18%
Inhibition=-2.07%
Inhibition=3.91%
Inhibition=-5.9%
Inhibition=-2.45%
Inhibition=-5.55%
Inhibition=6.31%
Inhibition=-1.08%
Inhibition=12.7%
Inhibition=0.37%
Inhibition=8.88%
Inhibition=11.63%
Inhibition=-1.96%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495582
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=13.77%
Inhibition=2.35%
Inhibition=21.17%
Inhibition=18.36%
Inhibition=5.381%
Inhibition=18.17%
Inhibition=10.15%
Inhibition=29.56%
Inhibition=18.27%
Inhibition=11.42%
Inhibition=15.4%
Inhibition=7.437%
Inhibition=-3.216%
Inhibition=18%
Inhibition=1.021%
Inhibition=16.4%
Inhibition=2.544%
Inhibition=19.11%
Inhibition=26.15%
Inhibition=5.133%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: BPDCN-GEN22
Protocol: A total of 500 exponentially growing Gen2.2 cells were seeded per well in 5 uL of media (RPMI + Glutamine, without phenol red plus10% FBS and 1X Pen/Strep) into 1536-well solid white high base tissue culture treated Greiner One Bio Plates (789173-F), using a multidrop combi dispenser and a small sterile cassette. Compounds and controls totaling 23nL per well (negative control DMSO and positive control 9.2 uM Bortezomib-final) were immediately added to the plates using a 1536 head pin tool from Kalypsys. The plates were then covered with stainless steel gasket lids from Kalypsys and incubated for 48 hours at 37C under 95% relative humidity with 5% CO2. After 48 hours, the plates were removed and allowed to reach room temperature before 3 uL of Cell Titer Glo reagent (Promega) were added using an Aurora Flying Reagent Dispenser Bioraptor. The plates were then spun at 1000 rpms to remove bubbles and incubated for 15 minutes at room temperature before reading on a ViewLux using a luminescent filter with a 10 second exposure. The relative luciferase units were used to calculated percent activity using DMSO as 100% and Bortezomib as 0%.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Activator9.349537.11450Partial curve; high efficacy; poor fit-5.02924.50450.3394139.866102.75152.30 0 0 0 0 0 0 1 0 0 188.0524128.0096112.723388.625579.246188.4591116.5125107.434240.612105.1422136.374988.0524QC'd by BIOMOL
Activator05142.8394114.1417111.508167.841110.3078162.3881116.8787143.5866138.3617142.280496.0848142.8394QC'd by BIOMOL
Activator0.0066105.25930Complete curve; high efficacy; poor fit-8.17920.70.8893112.3492217.60861.30 0 1 0 0 0 0 0 0 0 1149.7744206.0416175.796299.9709145.4635125.3281120.2334135.1946115.4803122.261890.372149.7744QC'd by BIOMOL
Activator0529.4231126.395381.16586.1405110.3352124.4199134.8609111.812889.3843231.3882107.438329.4231QC'd by BIOMOL
Activator05143.615387.7329109.6233117.133130.2435108.007371.945131.4159458.2894127.4181102.4514143.6153QC'd by BIOMOL
Activator20.931115.76070Partial curve; high efficacy; poor fit-4.67924.50450.672852.682168.44282.30 0 0 0 0 0 0 0 1 0 057.3383156.9875210.0745196.4426169.3007145.4793168.5143122.6219177.1228240.8839147.192657.3383QC'd by BIOMOL
Inactive0-4.87923.51170.74543.7363121.376141 0 0 0 0 0 0 0 0 0 04.995969.848372.4018110.8591122.5541161.1408130.7083144.5237100.537122.353447.45634.9959QC'd by BIOMOL
Activator11.7704120.38030Partial curve; high efficacy; poor fit-4.92924.95490.6857256.5786136.19822.30 0 0 0 0 0 0 0 0 0 1129.6573124.8033153.6337147.2807166.633130.3024101.8421144.7083155.0295116.7688231.6699129.6573QC'd by BIOMOL
Activator05123.0403128.8699210.7699190.2566146.8479215.4495109.2714124.0291164.0907204.8081137.4596123.0403QC'd by BIOMOL
Activator3.722132.65680Complete curve; high efficacy; poor fit-5.42924.95490.427689.2254121.88221.30 1 0 0 0 0 0 0 0 0 0100.467287.1822158.1858123.8552104.2031121.5711143.849137.3495134.381992.833779.7182100.4672QC'd by BIOMOL
Activator1.4818129.40820Complete curve; high efficacy; poor fit-5.82920.90.7836.537165.94521.30 0 1 0 0 0 0 0 0 0 042.5687179.6537123.5264118.8734141.6283179.6193162.418995.5446129.667848.147154.875542.5687QC'd by BIOMOL
Activator0.066223.89990Complete curve; high efficacy; poor fit-7.17924.95490.3972157.0608133.16091.30 0 0 0 1 0 0 0 0 0 0156.4182131.6383146.4008133.9209120.0163196.9193161.7274189.7061147.8016155.1127132.5334156.4182QC'd by BIOMOL
Activator1.662639.6820Complete curve; high efficacy; poor fit-5.77924.95490.639368.8456108.52751.30 0 0 0 0 0 0 0 1 0 058.2968104.901585.3011114.5667123.321105.330499.8094125.775785.4017139.460580.25458.2968QC'd by BIOMOL
Activator7.4266132.89130Complete curve; high efficacy; poor fit-5.12921.96730.519645.9316178.8231.30 0 0 0 0 0 1 0 0 0 046.3684155.3315110.8327150.523132.3744223.2312259.9272370.7888225.3172120.431280.827846.3684QC'd by BIOMOL
Activator26.350664.97420Partial curve; high efficacy; poor fit-4.57924.50450.778765.5932130.56752.30 0 0 0 0 0 0 1 0 0 070.9665137.7579130.009140.9582142.8709108.0684128.1229122.723883.1025134.1418125.198170.9665QC'd by BIOMOL
Activator0.066242.96070Complete curve; high efficacy; poor fit-7.17924.95490.3774171.918128.95731.30 0 0 0 1 0 0 0 0 0 0186.2327131.3763114.3898169.2145100.0259417.4076185.7832137.3011196.8317196.7498128.9228186.2327QC'd by BIOMOL
Activator20.931357.07590Partial curve; high efficacy-4.67921.62660.9443496.1622139.08632.10 0 0 0 0 0 0 0 0 0 0450.0879120.9857123.3915150.1624127.9468154.6912129.5912127.2593186.5804191.2598245.2113450.0879QC'd by BIOMOL
Inactive0-5.52923.19250.683822.4254105.728640 0 0 0 0 1 0 0 0 0 026.507899.36974.653492.2028101.995999.5674165.511173.039787.234839.914614.050826.5078QC'd by BIOMOL
Activator4.685957.81330Complete curve; high efficacy; poor fit-5.32924.95490.7192154.795696.98231.30 0 0 1 0 0 0 0 0 0 0156.374697.7645116.034697.6905140.541797.0357110.7006102.992857.4166132.01153.4092156.3746QC'd by BIOMOL
Activator23.48541.33940Partial curve; high efficacy; poor fit-4.629210.526488.6415129.98092.30 1 0 0 0 0 0 0 0 0 097.9229133.620896.1141131.6403139.2531128.2736113.9247123.5101139.3218112.8157122.812997.9229QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: BPDCN-CAL1
Protocol: A total of 500 exponentially growing Cal-1 cells were seeded per well in 5 uL of media (RPMI + Glutamine, without phenol red plus10% FBS and 1X Pen/Strep) into 1536-well solid white high base tissue culture treated Greiner One Bio Plates (789173-F), using a multidrop combi dispenser and a small sterile cassette. Compounds and controls totaling 23nL per well (negative control DMSO and positive control 9.2 uM Bortezomib-final) were immediately added to the plates using a 1536 head pin tool from Kalypsys. The plates were then covered with stainless steel gasket lids from Kalypsys and incubated for 48 hours at 37C under 95% relative humidity with 5% CO2. After 48 hours, the plates were removed and allowed to reach room temperature before 3 uL of Cell Titer Glo reagent (Promega) were added using an Aurora Flying Reagent Dispenser Bioraptor. The plates were then spun at 1000 rpms to remove bubbles and incubated for 15 minutes at room temperature before reading on a ViewLux using a luminescent filter with a 10 second exposure. The relative luciferase units were used to calculated percent activity using DMSO as 100% and Bortezomib as 0%.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Activator0596.9812124.7788111.862799.1911109.8132115.8543122.7029124.978711.9636106.6618115.3296.9812QC'd by BIOMOL
Activator5.899218.55230Partial curve; high efficacy; poor fit-5.22921.59360.403698.2719116.82422.30 0 0 0 0 0 0 0 0 0 1112.1416116.3242116.0395124.1925105.021117.4347113.456126.6776109.8792109.999101.2806112.1416QC'd by BIOMOL
Activator0.0053140Complete curve; high efficacy; poor fit-8.27921.010.4672116.3066102.30661.30 0 0 0 0 0 0 0 0 0 0115.6225103.8066106.9288110.734112.8603113.7842118.7801117.453127.3511110.7768108.9356115.6225QC'd by BIOMOL
Inactive0-4.77922.72020.92567.4047112.261140 0 0 0 0 0 0 0 0 0 011.761291.0017111.0572112.5676117.0089126.6768110.9798121.4511106.8272107.246267.780211.7612QC'd by BIOMOL
Activator05113.2428112.6901103.509103.9003102.6066116.1617101.937105.552969.0952107.2108101.4004113.2428QC'd by BIOMOL
Inactive0-4.77923.1320.95268.0992113.058640 0 0 0 0 0 0 0 0 0 03.8949109.004119.742107.3798101.7335102.3462118.5813117.9993118.1915117.629571.87863.8949QC'd by BIOMOL
Inactive0-4.87921.75290.9755-3.302111.272940 0 0 0 0 0 0 0 0 0 09.2164111.826113.9215114.6486108.2664119.8515109.8219108.562295.88998.580743.56689.2164QC'd by BIOMOL
Activator16.626124.87630Partial curve; high efficacy; poor fit-4.77921.69240.347492.6528117.5292.30 0 0 0 0 0 0 0 0 0 095.2635108.3173105.9493113.7331109.0795117.0458137.3809129.6073122.6355108.5839108.131495.2635QC'd by BIOMOL
Activator05112.755117.1575116.8914112.2579112.3712121.4293115.3043115.3089107.1441121.4021110.4386112.755QC'd by BIOMOL
Inactive0-4.77922.18760.988510.0687113.747640 0 0 0 0 0 0 0 0 0 017.4423109.6122112.2788114.0082120.8283115.6809111.1114117.7232111.2532104.416766.142317.4423QC'd by BIOMOL
Inactive0-5.52924.50450.98317.5135117.599740 0 0 0 0 0 0 0 0 0 012.8583129.2377109.7349118.9217115.1912116.2997113.6696110.2515109.547223.646124.047512.8583QC'd by BIOMOL
Activator18.654846.19170Partial curve; high efficacy; poor fit-4.72924.50450.824765.8443112.03612.30 0 0 0 0 0 0 0 0 0 066.877599.5341112.8886111.9402121.8966115.7352104.7994116.4969106.3102117.563697.729766.8775QC'd by BIOMOL
Activator23.48562.95570Partial curve; high efficacy; poor fit-4.62924.0950.872243.341106.29672.30 0 0 0 0 0 0 0 0 0 048.3003107.43119.6331100.973899.0434113.2845112.3172103.148797.5313103.168398.057948.3003QC'd by BIOMOL
Inactive0-6.17920.90.991413.9467122.275740 0 0 0 0 0 0 0 0 0 016.0493121.1837125.2456121.294112.6383110.2161103.73666.18643.993533.762219.090416.0493QC'd by BIOMOL
Inactive0-4.72922.72020.979810.0162112.861540 0 0 0 0 0 0 0 0 0 012.0535113.9203107.621117.2056105.2005113.2177112.1472115.6483117.9416106.765277.54812.0535QC'd by BIOMOL
Activator10.490433.93550Complete curve; high efficacy; poor fit-4.97924.95490.813387.1253121.06091.30 0 0 0 0 0 0 0 0 0 087.3266113.333118.7195122.2141120.0529128.8421109.7936131.8841120.4381122.173491.04487.3266QC'd by BIOMOL
Activator05106.0617105.1595.4872110.3326113.665116.9489116.2338108.1254105.7991103.2361100.4977106.0617QC'd by BIOMOL
Inactive0-5.97921.10.982913.892796.744840 0 0 0 0 0 0 0 0 0 017.662101.545396.414590.127794.5053100.607678.9371.978945.24927.207613.540717.662QC'd by BIOMOL
Activator0.74275.43280Complete curve; high efficacy; poor fit-6.12924.95490.4642117.2092111.77641.30 0 0 0 0 0 0 0 0 0 1111.9075115.2092111.9615115.9844108.9243109.7763107.7652113.0327118.4395118.7792114.168111.9075QC'd by BIOMOL
Activator05109.5103113.4756109.9484115.0474114.0506116.6804107.3915105.6838121.9588114.747114.6431109.5103QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:G-protein coupled receptor 84
External ID: CHEMBL4343781
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2020
Volume: 63
Issue: 5
First Page: 2391
Last Page: 2410
DOI: 10.1021/acs.jmedchem.9b01339

Target ChEMBL ID: CHEMBL3714079
ChEMBL Target Name: G-protein coupled receptor 84
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
%max<=100%
%max=46%
%max=59%
%max=87%
%max=90%
%max=125%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:G-protein coupled receptor 84
External ID: CHEMBL4343782
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 2020
Volume: 63
Issue: 5
First Page: 2391
Last Page: 2410
DOI: 10.1021/acs.jmedchem.9b01339

Target ChEMBL ID: CHEMBL3714079
ChEMBL Target Name: G-protein coupled receptor 84
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
0.0591EC50=59.1nM
0.175EC50=175nM
0.0618EC50=61.8nM
0.276EC50=276nM
0.0524EC50=52.4nM
0.199EC50=199nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:G-protein coupled receptor 84
External ID: CHEMBL4343759
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J Med Chem
Year: 2020
Volume: 63
Issue: 5
First Page: 2391
Last Page: 2410
DOI: 10.1021/acs.jmedchem.9b01339

Target ChEMBL ID: CHEMBL3714079
ChEMBL Target Name: G-protein coupled receptor 84
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
1.93Ki=1930nM
0.108Ki=108nM
2.64Ki=2640nM
1.78Ki=1780nM
19.6Ki=19600nM
2.17Ki=2170nM
7.26E-4Ki=0.726nM
0.00298Ki=2.98nM
0.091Ki=91nM
Inhibition%Not Active
14IC50=14000nM
0.472Ki=472nM
10Ki>10000nM
2.19E-4Ki=0.219nM
6.26E-4Ki=0.626nM
3.24E-4Ki=0.324nM
0.00156Ki=1.56nM
7.0E-4Ki=0.7nM
46.3IC50=46300nM
0.11Ki=110nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MCC011
Protocol: A high-throughput screen was conducted in 1536-well white flat bottom plates (Corning) on a Kalypsys robotic system. Cell lines WAGA, MKL-1, MKL-2, MCC-13, MCC-26, UISO, HaCaT, HEK293T, CRL7250, and NIH-3T3 were screened against 2 small molecule annotated drug libraries NPC and MIPE in dose response (8 and 11 pt. respectively) measuring cell viability after 72 hours of incubation. Briefly, cell lines were dissociated with trypsin or accutase (MKL-1 and MKL-2 only), passed through a 40 micron cell-strainer, and then plated with a Multidrop Combi Reagent Dispenser (ThermoFisher) into 1,536 well plates and plated down at a starting density ranging from 50 cells/ uL (HEK293T), 80 cells/ uL (NIH-3T3), 100 cells /uL (MKL-1, MKL-2, MCC-13, MCC-26, HaCaT, CRL7250, and UISO), 250 cells/ uL (WAGA) in a final volume of 5 uL of media (MCC cells: RPMI 1640, Control cells: DMEM) supplemented with 10% FBS and 1X Pen/Strep. A 1,536 pintool (Kalypsys) was used to transfer 23 nL of compound in DMSO to the 1,536-well assay plates. After 72 hr incubation at 37 degree celsius, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a BiorapTR. Plates were incubated at room temperature for 10 min, transferred to a ViewLux (PerkinElmer) and the luminescence was recorded using an exposure time of 2 seconds. Relative luminescence units (RLUs) were normalized to in-plate controls (no cells as a positive (cytotoxicity) control, DMSO as negative control) and the normalized data was processed using NCATS in-house software.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000059000 uMActivity at 0.0000296505 uMActivity at 0.0000627629 uMActivity at 0.0001361338 uMActivity at 0.0003144137 uMActivity at 0.0006678285 uMActivity at 0.00124 uMActivity at 0.00266 uMActivity at 0.00558 uMActivity at 0.00707 uMActivity at 0.017 uMActivity at 0.031 uMActivity at 0.069 uMActivity at 0.181 uMActivity at 0.368 uMActivity at 0.597 uMActivity at 1.656 uMActivity at 1.863 uMActivity at 4.836 uMActivity at 9.224 uMActivity at 16.10 uMActivity at 45.96 uMActivity at 92.69 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uM
Inhibitor37.2212127.575310Single point of activity-4.42924.95490.9931-128.5776-1.0023-30 0 0 0 0 0 0 0 0 0 0-97.40730-4.332400
Inactive0.01329.42330-7.87920.70.50130.57671040 0 0 0 0 0 0 0 0 0 01.93587.145312.24143.02923.39297.25620.5823-2.85275.4621-1.3525-0.54921.9358
Inactive0.05933.8540-7.22920.40.62832.5-1.35440 0 0 0 0 0 0 0 1 0 17.57680.82459.716.2951-2.79521.778223.810718.618626.701-8.723728.99317.5768
Inhibitor37.221243.146710Single point of activity-4.42924.95490.9703-43.14670-30 0 0 0 0 0 0 0 0 0 0-32.62230000
Inactive00004-2.32246.8981-3.111413.08049.03891.9974.8517-1.51738.13746.73713.5409-2.3224
Inhibitor37.221295.834310Single point of activity-4.42924.95490.9646-96.6556-0.8213-30 0 0 0 0 0 0 0 0 0 0-73.22402.0597-7.5145-4.9351
Inactive00004-5.924613.9115-2.239922.3817-3.690217.64660.983-10.40496.39419.0991-4.1342-5.9246
Inhibitor26.350682.76740Partial curve; partial efficacy-4.57924.0950.8717-86.5714-3.8044-2.20 0 0 0 0 0 0 0 0 0 0-78.842-5.93801.3974-28.1211
Inactive000040.022410.248810.425-3.06316.088911.75171.77591.22993.8630.57482.4410.0224
Inactive3.31737.88330-5.47924.95490.5098-2.8833540 0 0 0 0 0 0 0 0 0 0-5.73613.93155.0136.2883-1.901311.20266.12033.29585.5784-2.02860.5573-5.7361
Inactive37.221215.87970-4.42924.95490.5221-17.3797-1.540 0 0 0 0 0 0 0 0 0 0-13.2331-1.0197-4.23261.5878-1.3704
Inactive0.06627.93390-7.17920.90.59320.56618.540 0 0 0 0 0 0 0 0 0 01.56674.512510.965311.77192.24175.45342.31084.412-1.6116-0.46240.62181.5667
Inactive0.132125.77010-6.87924.95490.559-15.700910.069240 0 0 0 0 0 0 0 0 0 0-20.7968-1.38432.39852.132723.511324.9349-16.09082.2208-21.3286-30.7571-5.6999-20.7968
Inactive000040-2.3996-4.4114-2.0746-4.8678
Inactive0.66194.58310-6.17922.72020.3338-1.08313.540 0 0 0 0 0 0 0 0 0 14.56861.8671-0.85384.05730.46459.58014.53941.4181-0.6516-1.3193-0.67644.5686
Inactive000040-0.800500.13270.7944
Inactive0000414.25472.5411.436-2.13565.219813.942315.81650.97664.85062.1093-0.697614.2547
Inactive000040-49.4569-14.24420-2.3916
Inactive0.833321.05840-6.07921.37230.9479-17.0584440 0 0 0 0 0 0 0 0 0 1-3.30275.89232.6361.32297.05843.94520.8401-3.7291-9.8453-18.382-14.8977-3.3027
Inactive000040.99194.0284.60455.0511-2.99924.45879.54511.8796-2.51456.0782-1.32220.9919
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF001
Protocol: HEK 293, NIH 3T3, CRL-7250, HACAT and KB 3-1 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250, 400, 500, 500, 500 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.176 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.372 uMActivity at 1.908 uMActivity at 4.964 uMActivity at 9.273 uMActivity at 17.43 uMActivity at 44.77 uMActivity at 91.96 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000073700 uMActivity at 0.0000316373 uMActivity at 0.0000755538 uMActivity at 0.0001736587 uMActivity at 0.0003606937 uMActivity at 0.0007618542 uMActivity at 0.00133 uMActivity at 0.00262 uMActivity at 0.00635 uMActivity at 0.00856 uMActivity at 0.017 uM
Inactive0-6.08624.95490.8467-19.0684-1.540 0 0 0 0 0 12.118100-8.34361.8417-20.8904-17.20922.1181
Inactive00043.093704.02863.4263-3.42834.65930.95863.0937
Inactive0-8.43624.95490.60020-10.442940 0 0 0 0 0 1-5.6741-7.8694.8276000-3.665-5.6741
Inactive0004-1.22691.59440.8268-6.8139003.009-1.2269
Inactive00040000.646
Inactive00042.016104.739100.507404.00372.0161
Inactive00040-58.9387-0.658900.7761-3.050100
Inactive0-5.38623.57220.9641-17.9156140 0 0 0 0 0 10001.05953.84450-17.0130
Inactive0004-1.61750000-31.91564.5285-1.6175
Inactive000403.5826.95880
Inactive00044.1629-0.06810-0.13403.503204.1629
Inactive00040.0775-4.4477004.2892-3.083200.0775
Inactive0004-4.2864-6.2990000-3.464-4.2864
Inhibitor20.230130.466710Partial curve; partial efficacy; poor fit-4.6944.95490.9513-30.9667-0.5-2.40 0 0 0 0 0 0-27.47223.59671.00910-2.7438-3.3305-0.4297-27.4722
Inactive000406.34610
Inactive0004-5.47750-1.336404.40630-3.1548-5.4775
Inactive00042.2138-0.3090-3.3277-5.07761.864902.2138
Inactive0004-6.8569-2.008600000-6.8569
Inhibitor20.2301111.05610Single point of activity-4.6944.95490.9964-109.52221.5338-30 0 0 0 0 0 0-97.61333.530.1744-1.61494.641802.914-97.6133
Inactive0-4.6944.95490.8369-20.4658340 0 0 0 0 0 0-17.88822.63860
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4513082
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0.24%
Inhibition=4.58%
Inhibition=-0.3%
Inhibition=-0.3%
Inhibition=-0.04%
Inhibition=-0.04%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=0.03%
Inhibition=0%
Inhibition=0.03%
Inhibition=0%
Inhibition=-0.27%
Inhibition=-0.27%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=14.41%
Inhibition=0.39%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1B1
External ID: CHEMBL3039488
Protocol: N/A
Comment: Journal: Mol Pharmacol
Year: 2013
Volume: 83
Issue: 6
First Page: 1257
Last Page: 1267
DOI: 10.1124/mol.112.084152

Target ChEMBL ID: CHEMBL1697668
ChEMBL Target Name: Solute carrier organic anion transporter family member 1B1
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=65.85%
Inhibition=63.37%
Inhibition=75.25%
Inhibition=97.38%
Inhibition=105.26%
Inhibition=97.94%
Inhibition=105.32%
Inhibition=99.4%
Inhibition=101.01%
Inhibition=86.27%
Inhibition=80.06%
Inhibition=89.01%
Inhibition=120.91%
Inhibition=102.46%
Inhibition=101.26%
Inhibition=90.74%
Inhibition=113.76%
Inhibition=82.92%
Inhibition=126.2%
Inhibition=116.63%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Aryl hydrocarbon receptor
External ID: CHEMBL5250020
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2022
Volume: 244
First Page: 114845
Last Page: 114845
DOI: 10.1016/j.ejmech.2022.114845

Target ChEMBL ID: CHEMBL3201
ChEMBL Target Name: Aryl hydrocarbon receptor
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.05Kd=50nM
1.3E-4Kd=0.13nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2mCherry
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral ininfection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times postinfection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.53 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.39870.9996-13.0836-0.585340 0 0 1-0.8016-2.9877-9.467-12.5697-0.8016QC'd by "Asinex Ltd."
Inhibitor12.589340.511110Single point of activity-4.94.50450.9991-45.3562-4.8451-30 0 0 0-45.0493-5.3378-3.9936-8.2693-45.0493QC'd by "Asinex Ltd."
Inactive040-2.0352000QC'd by "Asinex Ltd."
Inactive04000-0.99410QC'd by "Asinex Ltd."
Inactive04.954910-13.633540 0 0 00-12.1946000QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive04-13.3369-12.1444-5.0835-13.8274-13.3369QC'd by "Asinex Ltd."
Inactive040-4.5112-3.956800QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive01.80790.9998-19.4131.540 0 0 1-2.29920-11.3763-18.6775-2.2992QC'd by "Asinex Ltd."
Inactive04.95490.77214-15.639840 0 0 00-10.469-15.9421-20.94990QC'd by "Asinex Ltd."
Inactive04.95490.9987-20.1455-0.540 0 0 0-19.28790-0.8113-0.6866-19.2879QC'd by "Asinex Ltd."
Inactive04.95490.9999-7.3207040 0 0 0-6.934000-6.934QC'd by "Asinex Ltd."
Inactive04-10.13410-23.8022-3.1543-10.1341QC'd by "Asinex Ltd."
Inactive01.82650.9999-31.5926140 0 0 1-8.44790-12.323-29.2439-8.4479QC'd by "Asinex Ltd."
Inactive00.70.95422-18.098140 0 0 00-15.9151-9.0083-6.24390QC'd by "Asinex Ltd."
Inactive04.95490.79940.5884-8.240 0 0 0-1.1763-9.1365-5.7126-9.75-1.1763QC'd by "Asinex Ltd."
Inactive00.60.9653-16.23140.75640 0 0 0-14.3595-3.5367-8.6422-10.5182-14.3595QC'd by "Asinex Ltd."
Inactive04-3.3063-1.5829-0.45720-3.3063QC'd by "Asinex Ltd."
Inactive04.95490.7973-6.6878-1.540 0 0 10-2.54350-5.57310QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Solute carrier organic anion transporter family member 1B3
External ID: CHEMBL3039491
Protocol: N/A
Comment: Journal: Mol Pharmacol
Year: 2013
Volume: 83
Issue: 6
First Page: 1257
Last Page: 1267
DOI: 10.1124/mol.112.084152

Target ChEMBL ID: CHEMBL1743121
ChEMBL Target Name: Solute carrier organic anion transporter family member 1B3
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=89.51%
Inhibition=81.71%
Inhibition=65.47%
Inhibition=50.32%
Inhibition=112.43%
Inhibition=99.94%
Inhibition=101.75%
Inhibition=98.72%
Inhibition=104.08%
Inhibition=114.2%
Inhibition=97.5%
Inhibition=120.61%
Inhibition=45.56%
Inhibition=105.72%
Inhibition=107.28%
Inhibition=93.09%
Inhibition=84.51%
Inhibition=155.79%Outside typical range
Inhibition=97.26%
Inhibition=72.91%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2Venus
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral infection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times post-infection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.52 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.46410.71-12.454-240 0 0 0-11.2117-5.20930.6206-7.2594-11.2117QC'd by "Chem Div"
Inactive04-11.3429-16.0267-12.2608-14.6132-11.3429QC'd by "Chem Div"
Inactive01.62590.9272-14.3148-0.87740 0 0 0-15.2623-7.8142-13.6096-13.0621-15.2623QC'd by "Chem Div"
Inactive04-12.3142-9.814-12.586-8.4662-12.3142QC'd by "Chem Div"
Inactive04-8.2677-9.1999-12.2836-11.2753-8.2677QC'd by "Chem Div"
Inactive04.50450.9238-23.3577-9.005740 0 0 0-23.2147-6.6714-11.5717-9.7492-23.2147QC'd by "Chem Div"
Inhibitor11.220218.895721Partial curve; partial efficacy-4.953.51170.9065-31.7758-12.8801-2.20 0 0 0-31.4798-16.0985-9.0667-16.5103-31.4798QC'd by "Chem Div"
Inactive04.95490.8003-13.5254-8.878340 0 0 0-13.3545-10.4528-7.3986-12.9731-13.3545QC'd by "Chem Div"
Inactive02.33320.9015-5.5393840 0 0 0-5.44945.481810.30710-5.4494QC'd by "Chem Div"
Inactive01.96730.9741-21.6735-12.493740 0 0 0-21.3946-13.4008-12.078-16.6303-21.3946QC'd by "Chem Div"
Inactive04-5.6419-17.3934-2.7552-14.5706-5.6419QC'd by "Chem Div"
Inactive04.95490.8944-16.0102-8.684840 0 0 0-15.0085-7.2373-9.9603-8.6791-15.0085QC'd by "Chem Div"
Inactive01.55790.9997-19.5854-2.051340 0 0 1-5.8527-2.9594-9.4187-17.9878-5.8527QC'd by "Chem Div"
Inactive00.90.997418-20.238340 0 0 012.7737-17.6986-10.21151.105512.7737QC'd by "Chem Div"
Inactive01.88510.9998-14.291-6.778340 0 0 1-6.726-6.8986-8.4505-13.1591-6.726QC'd by "Chem Div"
Inactive00.90.9901-24.8053-6.556940 0 0 0-19.0044-6.7141-9.2211-12.2131-19.0044QC'd by "Chem Div"
Inhibitor1025.752521Partial curve; partial efficacy-54.95490.9958-34.5683-8.8157-2.20 0 0 0-34.709-9.7184-7.7631-13.3604-34.709QC'd by "Chem Div"
Inactive00.50.7446-13.2445-2.110940 0 0 0-9.3704-2.5924-6.2168-4.8236-9.3704QC'd by "Chem Div"
Inactive04.95490.8017-7.4285-18.016840 0 0 0-7.4434-13.764-5.7738-9.5578-7.4434QC'd by "Chem Div"
Activator31.6228490Partial curve; high efficacy-4.50.80.9998651142.10 0 0 1118.3965112.9568110.0983102.4909118.3965QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1035069
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2003
Volume: 66
Issue: 11
First Page: 1520
Last Page: 1523
DOI: 10.1021/np030288g

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityNot Active
ActivityNot Active